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Summary
Combined ultrafast 90°+90° kV-MV cone-beam computed tomography (CBCT)
within breath-hold of 15s is a promising approach to accelerate imaging for patients
with lung tumors treated with deep inspiration breath-hold (DIBH). To judge clinical
feasibility of kV-MV CBCT, two main properties have to be fulfilled: (1) image
quality has to be sufficient for registration within 1mm accuracy, and (2) dose
exposure has to be small compared to the prescribed dose.
The aim of this thesis was to develop concepts to test these properties of kV-MV
CBCT based on a comparison study to clinically established CBCT methods. In
particular, the main aspects were accomplished as follows:
Dosimetric properties: For a reliable measurement of the absorbed dose in the
imaging process, accurate dose calibration was performed for kV and MV energy.
Extensive research was done to determine beam quality for both energy ranges. For
direct comparison of MV and kV dose output, the relative biological effectiveness was
considered. To simulate the patient situation, measurements in various representative
locations of an inhomogeneous thorax phantom were performed. Furthermore, the
CT dose index (CTDI) was determined for future quality assurance purposes. A
measured dose of 20.5mGE in the target region was comparable to the widely-used
clinical imaging technique, whereas kV-MV spared healthy tissue and reduced dose to
6.6mGE (30%). These results show that from the dosimetric point of view, kV-MV
CBCT is suitable for hypofractionated DIBH.
Registration accuracy: A detailed phantom registration study was performed with
different tumor-mimicking tumor-shapes in an inhomogeneous thorax phantom. 10
random pre-selected isocenter shifts were applied using optical tracking with high
accuracy of 0.05mm. Registration was performed with three methods: (1) manual,
(2) automatic software provided by manufacturer, and (3) self-developed automatic
registration framework. An objective evaluation was achieved with the self-developed
registration method by automatic determination of identical region of interest around
the tumor-shapes for all imaging techniques. Registration accuracy was in average
maintained below 1mm, with maximum outliers still below 1.5mm.
In summary, the comparison studies conceptualized and accomplished in this thesis
demonstrated that kV-MV CBCT is feasible for imminent clinical implementation.
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Preamble
Ultrafast combined kilovoltage-megavoltage cone-beam CT (kV-MV CBCT) was
developed in our institution by a small research group. The proof-of-principle was
published by Blessing et al. [18]. My contribution as a co-author was the stabilization
of automated stripe-artifact detection, based on a part of my Diploma thesis [9]. The
first steps towards synchronized kV-MV CBCT were published by Wertz et al. [99].
The final automated implementation was accomplished as part of the PhD thesis of
a colleague within our research group [16]. An end-to-end test of fully automated
kV-MV CBCT was presented orally on ESTRO annual meeting [15], a publication
about the final automated workflow was recently submitted to a peer-reviewed
journal [17]. In both conference abstract and publication, my contribution as second
author was to engage in optimization of linac parameters for stable MV dose output
achievement.
Presentations of interim results of this thesis were given on several conferences. The
interim dosimetrical and geometrical aspects of novel kV-MV CBCT (section 2.3)
on an inhomogeneous thorax phantom were presented as a poster at the ASTRO
annual meeting [5] and as an oral presentation at the DGMP annual meeting [8],
including measurements of CT dose index. A poster about interim registration
accuracy results was presented at ASTRO annual meeting [6]. The dosimetry and
registration accuracy measurements were further improved, measurement calibration
and performance accuracy was refined, and evaluation methods were developed and
executed. The study on registration accuracy (section 2.5) was recently accepted
for publication1 [7]; the study of kV-MV CBCT dosimetry (section 2.3) will soon be
submitted for publication. The contents (some wording, figures, tables) of the study
on registration accuracy in this thesis are adopted from the submitted article [7].
1The final publication is available at Springer via http://dx.doi.org/ [10.1007/s00066-016-0947-
2].
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1 Introduction
Lung cancer remains the leading cancer-induced cause of death worldwide for both
male and female [41,90]. In 2015, the estimated lung cancer morbidity rate was 13%
of all cancer diagnoses (N≈ 1.8 million), resulting in lung cancer being the second
most likely new cancer site. Every third cancer-induced death is caused by lung
cancer. Non-small cell lung cancer (NSCLC) covers 80% of the new annual lung
cancer diagnoses, and 20% of these have early-stage disease and thus the best chance
for cancer cure [90]. If applicable, lung cancer treatment is carried out by surgery.
In case the tumor is inoperable or other reasons eliminate a surgical procedure,
radiotherapy (RT) is an appropriate alternative. Mortality rates however remain
very high with conventional fractionated external beam radiotherapy (EBRT) [27].
With the advent of image-guided intensity-modulated radiotherapy (ig-IMRT) and
further breakthroughs in RT technology, the over the last decades clinically well-
established stereotactic ablative radiotherapy (SABR) of brain metastases was ex-
panded to extracranial tumor lesions, such as lung metastases or NSCLC [23,43, 96].
Indispensable advances in RT technology for extracranial hypofractionated SABR
were:
• Tumor definition: broad selection of diagnostic imaging techniques, such as
computed tomography (CT), magnetic resonance imaging (MRI) and positron
emission tomography (PET/CT)
• Radiotherapy treatment planning: IMRT with dynamic multi-leaf collimator
(MLC) from different gantry angles or volumetric modulated arc therapy
(VMAT), determined by high-quality calculation algorithms, leading to steep
dose gradients between tumor and healthy tissue (e.g. inverse planning based
on Monte Carlo algorithms [11])
1
1 Introduction
• Image guidance: reproducible patient positioning with accurate motion man-
agement during imaging and treatment plan delivery
• Treatment delivery: precise maintenance and quality assurance (QA) of linear
accelerator (linac) and imaging system
Besides being time-efficient and technologically on the highest level, SABR achieves
excellent radiobiological outcomes: tremendous local tumor control probability (TCP)
and substantially lower normal tissue complication probability (NTCP), leading to an
increased therapeutic window [43,96]. Hypofractionated high-dose ig-SABR (image-
guided SABR) treatment outcomes are more promising than normofractionated
3D-conformal RT (3D-CRT) and show good results with less toxicity to normal tissue
(less pneumonitis of lung) while applying ablative doses to the tumor [27,29].
Recently, SABR treatment times were reduced significantly to the technically fastest
limits at present by introducing the flattening-filter-free (FFF) irradiation technique,
which can reach high dose-rates. Thus, treatment times changed over time from
60−90min for the initial SABR-technique with stereotactic body fixation [43], to
20−30min with ig-IMRT [13,25] and finally 3−5min beam-on times with FFF for
fractional doses of 5−20Gy [22, 25,42,82,92].
Essential pre-requisite for successful high-dose lung SABR is appropriate and reliable
image guidance (IG) as well as meticulous breathing-induced motion management.
The most common IG technique used in clinical routine for pre-treatment target
localizations is a kilovoltage (kV) CBCT perpendicularly mounted to the linac [24,60].
In rare cases Megavoltage cone-beam CT (MV-CBCT) [79, 85] is applied instead,
however, MV-CBCT is not popular due to reduced soft-tissue contrast.
Seppenwoolde et al. [88] described in detail the remarkable respiratory motion
trajectories of lung tumors. The largest motion amplitude of in average (12±2)mm
was observed in craniocaudal (CC) direction for tumors in the lower lobe, not attached
to any rigid structures. Motion in right-left (RL) and anterioposterior (AP) directions
were smaller with in average (2±1)mm. Breathing patterns differed from patient to
patient, and also inter- and intrafractionally for one patient considering magnitude
and breathing period [29,61,88,91].
For compensation of breathing motion in lung SABR, the AAPM TG report 76 [61]
summarizes a variety of methods for motion management. The most prominent ones
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are gating [46, 76], tracking [30, 93], formation of an internal target volume (ITV)
based on a 4D CBCT [47,70,95] or breath-hold strategies such as deep inspiration
breath-hold (DIBH) [13,23,67,77,102].
Gating and real-time tracking methods adjust the treatment beam delivery to the
breathing cycle of the patient, either by only delivering dose when the tumor is
in the gated window [46, 76], or by following the tumor with a robotic arm (e.g.
CyberKnife) [30, 93]. Both methods increase treatment times as well as imaging
dose exposure due to constant tracking of the tumor. The motion of organs at risk
(OAR) however is not considered. The application is complicated and needs extensive
individual modelling to consider tumor deformation and potential tracking delay.
The 4D treatment based on the ITV concept not only increases imaging and treat-
ment time, but also enlarges the planning target volume (PTV). The ITV covers
the whole breathing cycle from end-exhale to end-inhale phase, resulting in a large
target volume and thus more irradiation of surrounding healthy tissue [47, 70, 95].
The ICRU report 62 provides further details on target definitions and margins [1].
The large amount of data and the complex workflow may limit the clinical usage.
Breath-hold strategies and especially DIBH have several dosimetric and methodical
advantages. Breath-hold gating simplifies RT performance most by tumor immobi-
lization and smallest PTV. The static tumor position is highly reproducible [67] and
thus treatment planning and delivery need no further data evaluation and motion
considerations. The tumor being a conformal ”fixed target” facilitates treatment
planning and improves sparing of OAR [22, 74]. Especially for the case of deep
inspiration breath-hold (DIBH), both cardiac and lung toxicity can be reduced
because the diaphragm pulls the heart away from the breast, and the lung (as one of
the most radiation-sensitive organs) is enlarged to 70−80% vital capacity, leading
to only a small part of the lung being within beams-eye view [61]. Since no further
imaging during treatment is required, imaging dose is smallest for DIBH strategy.
In our institution (University Medical Center Mannheim, UMM, Mannheim, Ger-
many), hypofractionated ig-SABR is usually combined with computer-assisted breath-
hold gating (DIBH). Conservative hypofractionation of 5× 12Gy (peripheral) or
12×5Gy (central) applied dose to the tumor is usually applied to small lung lesions
of diameters < 5cm. Narrow residual PTV margins of 5mm in radial, and 10mm in
longitudinal direction are common. Inverse treatment planning and dose calculation
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based on Monte Carlo algorithms can achieve steep dose gradients between lung
lesions and surrounding organs at risk [20,91]. Individual breath-hold time-frames of
our patients are 10−20s. Treatment beams are delivered with FFF-technique, lead-
ing to very fast plan delivery of approximately 2−4min, excluding the approximately
3−8 interruptions for free breathing [25,92].
Hence, fast and reliable hypofractionated image-guided breath-hold SABR of lung
lesions with FFF technique is successfully implemented into clincal routine. The
only remaining weak point in the daily treatment chain is the slow pre-treatment
imaging under repeated breath-hold, which still offers room for improvement and
leads to the scope of this thesis. The combination of CBCT image-guided patient
positioning, hypofractionated lung SABR treatment and computer-assisted breath-
hold gating resulted in excellent treatment outcomes [20,67]. With FFF-treatment
beam delivery technique, utmost acceleration of treatment was achieved. Current
imaging techniques, however, still lack of acceleration improvement, leading to
imaging taking as long as the treatment delivery itself.
Initially, continuous CBCT image acquisition was performed in repeated breath-hold,
generating a volume reconstructed from 65% breath-hold phases and acceptable
image quality with small motion artifacts. Acquisition times of 40−120s are beyond
the ability of most patients to hold their breath [21].
A new version of CBCT-software improves image quality by allowing the CBCT
system to interrupt image acquisition in phases of spontaneous breathing. These
multiple breathing interruptions however lead to an even longer imaging time (up to
3−4min) [19, 92]. A non-clinical kV-CBCT preset with minimum requirements such
as gantry rotation of 180° (+ cone-angle) in accelerated rotation speed would still
need 30s for image acquisition and thus requires most likely more than one breathing
interruption. To prevent image quality degradation through residual motion artifacts
caused by repeated breath-hold imaging and to further improve patient comfort,
CBCT image acquisition within one single breath-hold phase (typically between
10−20s) would be ideal.
In our department, dynamic imaging of low-dose combined kV-MV CBCT was
recently developed [18,99]. This single breath-hold ultrafast kV-MV CBCT imaging
(∼ 15s), target re-positioning (∼ 2min) and DIBH FFF-SABR (∼ 2−4min) would
reduce the total treatment to ≤ 15min. Ultrafast kV-MV CBCT development was
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recently completed by our small team of researchers and is now ready to be introduced
in clinical routine. A paper on the finalized implementation of kV-MV was recently
submitted for puplication [17].
Towards legal approval as in-house medical product and towards clinical implemen-
tation and a first patient-trial, our novel kV-MV CBCT imaging method had to be
evaluated and compared with conventional, clinically established techniques based
on phantom studies.
In this thesis, characterization, concept development, accomplishment and evaluation
by means of specific "acceptance tests" of our novel kV-MV CBCT imaging technique
was performed regarding (1) applied imaging dose, (2) image quality and (3) image
registration for patient positioning accuracy.
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For legal approval of novel kV-MV CBCT and to pave the way for implementation into
clinical routine, several aspects of acceptance tests had to be performed and compared
with conventional, clinically established techniques. The concept development,
accomplishment and evaluation of these comparison tests based on phantom studies
were the aim of this thesis.
In section 2.1, a detailed survey of kV-MV CBCT development is presented, from
initial idea to final automized workflow ready for evaluation of clinical applicability
and competitiveness with other CBCT imaging techniques. These clinical and non-
clinical CBCT imaging techniques are introduced in section 2.2. Novel kV-MV
CBCT was compared with these in all applied acceptance tests. Thereafter, the
measurement concepts, the performance and the evaluation methods of the three
acceptance tests are described: (1) dosimetry (2.3), (2) image quality (2.4) and (3)
registration accuracy (2.5).
All measurements were performed in static phantom position. KV-MV is delivered
within one breath-hold, therefore no residual tumor motion is expected. The other
imaging techniques exceeding single breath-hold time were also measured in static
position, to compare kV-MV with the best-achievable image quality and to not
unnecessarily complicate the measurement execution.
Primarily, the measurements in this thesis were conducted on a clinically commis-
sioned treatment Elekta Synergy linac (Integrity 1.2) equipped with a foldout MV
detector iView GT v3.4 as well as a perpendicularly mounted kV-CBCT XVI v4.2.2
(all Elekta AB, Stockholm Sweden). This main linac is in the following called
”LINAC1”. Only in the dosimetry study (2.3), a newer version of kV-CBCT was
additionally compared with. This latest available CBCT software version XVI v5.0.2
was installed on a clinical Elekta VersaHD linac, in the following called ”LINAC2”.
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2.1 Novel ultrafast combined kV-MV CBCT: survey
from initial idea to final workflow
The initial idea to combine kV and MV beam CBCT was presented by Yin et al. [104].
However, they only realized a step-and-shoot method. With our novel method of
ultrafast combined low-dose kV-MV CBCT [18], the gantry dynamically rotated only
90° and thus significantly reduced image acquisition time to approximately 15s. The
development of kV-MV CBCT was accomplished on LINAC1. Image acquisition was
performed simultaneously, creating 90° kV and 90° MV projections. Thus, a full
180° volume data set was acquired and reconstructed by filtered backprojection. Our
additional in-house developed hardware system managed kV and MV detector panel
readout signals [99] and hence synchronized kV and MV image acquisition. The
kV-MV CBCT imaging strategy was automated to be performed in real-time [15,16].
In the following subsections, a short survey of the development of ultra-fast combined
kV-MV CBCT imaging is provided, from the initial idea to proof of principle to final
automated version.
2.1.1 Initial idea: step-and-shoot combined kV-MV CBCT by
Yin et al.
The initial idea to combine the kV CBCT imaging system together with the MV
treatment beam and the corresponding portal imaging detector was presented by
Yin et al. in 2005 [104]. Their motivation to aggregate both imaging modalities
were (1) image acquisition time reduction by 50%, (2) inclusion of treatment beam
information in the patient position verification otherwise performed exclusively by
kV-CBCT, (3) streak artifact reduction based on metal parts in the patients’ body
by MV contribution.
The study was performed on a clinical Varian Clinac 21EX linear accelerator with
MV portal imager and kV On-Board-Imager (OBI) orthogonally mounted to the
linac gantry (all Varian Medical Systems CA, USA). The main achievements of this
study to develop an aggregated dual-energy kV-MV imaging method were:
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• KV and MV projection acquisition at identical beam orientations in step-and-
shoot mode with 2° steps over a 100° gantry arc (in total 48 kV and 48 MV
projections).
• Separated volume reconstruction with MLS-ART reconstruction algorithm [45].
• Combination of both kV and MV contribution by projection-based data con-
version, i.e. projections provided by overlapping area of cone-angle of 10° were
used to estimate conversion function.
Phantom measurement results were presented. However, the initial idea of dual
energy CBCT to save time during image acquisition could not be realized. The
limitations for clinical implementation of this study were:
• Image acquisition was performed oﬄine, kV and MV projections were acquired
sequentially in a step-and-shoot mode, increasing imaging time to a clinically
non-applicable time extent.
• MV dose output was 2MU per projection, i.e. 96 MU over the full 100° arc;
kV dose output was 100kVp and 0.5mAs per projection.
• The reconstruction algorithm MLS-ART [45] was slow compared to clinically
used Filtered Backprojection [40].
• MV contribution reduced soft-tissue contrast.
This study thus provided a proof-of-principle [104] and offered strong potential for
development of an on-line, continuous and fast kV-MV dual-energy CBCT imaging
method to be implemented into clinical routine.
2.1.2 Unsynchronized kV-MV CBCT: proof of principle
Our research group started the development of a clinically applicable combined
kV-MV CBCT imaging technique based on continuous gantry rotation and low
MV-dose output on LINAC1 in 2008 [18]. Simultaneous acquisition of both kV
and MV projections during continuous gantry rotation was realized in accelerated
mode, requiring only 15s for a 90° scan. To achieve low MV dose output, linac
parameters such as gun current and tuner rest had to be adapted. The linac
parameters were manually entered in the linac control software; by trial and error, a
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suitable parameter setting was established. The lowest MV dose output still providing
sufficient image quality was 8.25MU for 40 MV projections, i.e. 0.21MU/projection.
A dose estimation resulted in 82.5mGy for the 90° scan [18]. The kV contribution
was set up by adapting a clinically established preset to our requirements (smallest
possible dose output, 90° gantry rotation). The dose output of the kV contribution was
thus comparatively small with an estimated dose of 6mGy for 60 kV projections [18].
The biggest challenges however were the data handling of the MV contribution.
Since the MV treatment beam and the portal imaging detector were not designed
for continuous readout, projection angle information was missing and stripe artifacts
occurred in the MV projection data. The stripe artifacts were introduced due to the
missing synchronization between MV detector readout and linac pulse irradiation, i.e.
during the readout time frame of the MV detector, the linac was pulsing multiple
times, leading to intensity fluctuations in each MV projection. A software workaround
was developed to correct for these stripe artifacts in a post-processing step of MV
data [18]. Unfortunately, the stripe artifact occurrence did not follow any systematic
scheme, thus, the software workaround based on simple gradient threshold method
was error-prone. The projection angle information was determined by attaching a
high-contrast ball-shaped marker next to the phantom and tracking the current angle
in the sinusoidal curve of the gantry rotation. The projection angle determination
was performed with an in-house developed marker tracking software [18]. However,
successful tracking was depending on the image quality of the MV projection data.
An expected spatial isocenter shift for different gantry angles due to continuous
gantry rotation and resulting mechanical forces acting on sources and detectors was
also corrected in a post-processing step of MV projection data.
To individually reconstruct both 90° kV and 90°MV projection data, a reconstruction
algorithm based on filtered backprojection [40] was implemented in-house on a
graphics processing unit using CUDA technology [18]. A reconstruction of 100
projections (according to 90° kV-MV CBCT) into 3D volume data took 6s. After
successful reconstruction, both volumes were combined by voxel-to-voxel addition,
resulting in a final combined kV-MV CBCT volume.
This proof-of-principle study of combined kV-MV CBCT was published in 2010 by
Blessing et al. [18]. Phantom measurements showed sufficient image quality and
the results convinced the linac manufacturer of the potential of ultrafast kV-MV
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CBCT imaging within one breath-hold phase of 15s. The manufacturer agreed to
collaborate with our research group and provide us with essential details about linac
control software, to replace the workarounds with an improved and reliable strategy.
2.1.3 Synchronized kV-MV CBCT
To overcome the problem of stripe artifacts in the MV projections, the linac pulsing
and the MV detector readout had to be synchronized. Therefore, a hardware was
developed which controlled the number of linac pulses per frame and defined the
point when to start MV detector readout. This dedicated synchronization hardware
was developed by a colleague in our research group, in close cooperation with the
linac manufacturer. The FGPA-based hardware allowed communication between
both independent kV and MV imaging subsystems. The kV panel trigger pulses
were used to synchronize the MV panel trigger. Furthermore, the linac pulsing was
controlled by the hardware, enabling low MV dose output. The system was described
in Wertz et al. [99].
The kV subsystem remained unchanged, the kV pulse rate of 180ms was used as a
clock for the hardware, i.e. each MV projection corresponded to a 90° shifted kV
projection. With the synchronization hardware, stripe artifact occurrence could be
eliminated. The linac parameters reducing the linac output to low MV-dose matching
with the triggered linac pulses provided by the hardware were entered manually in
the linac control software. Manual interaction was however not only error-prone, but
also required too much time. To successfully accomplish kV-MV CBCT imaging, all
required steps from initiating the kV and the MV beam to starting simultaneous
image acquisition had to be performed within a few seconds. Otherwise, several
interlocks, such as disabled simultaneous imaging of kV and MV mode, would be
re-activated. With the synchronization hardware, a low-dose linac output of 5MU
was achieved, resulting in an estimated MV dose exposure of approximately 60mGy
to the patient. The applied dose from the kV-contribution was expected to be
negligibly small, i.e. approximately 3mGy.
To correct for residual motion of the sources and detectors due to mechanical forces
occurring through continuous gantry rotation, the projection data had to be corrected
for spatial isocenter shifts. The CBCT software (XVI) already considered flexmap
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correction internally. For MV projection data, however, our research group had
to develop the flexmap data. The generation of the flexmap correction table was
performed in a similar procedure as for kV CBCT.
In Wertz et al. [99], the synchronized combined kV-MV CBCT imaging technique
was published. Phantom measurements were performed to evaluate kV-MV CBCT
for clinical feasibility. The results were compared with a non-clinical 360° kV-only
CBCT preset. It was determined that kV-MV CBCT provided sufficient image
quality for high-gradient areas such as in the lung. However, in this synchronized
combined kV-MV approach, a lot of manual interaction was still required, e.g. setting
of linac parameters, derivation of MV angles from kV database and introduction of
flexmap. Furthermore, full end-to-end workflow was not yet realized, the data post-
processing had to be performed oﬄine, and registration was not yet possible. Towards
clinical implementation, the final kV-MV CBCT workflow had to be automated, with
least possible manual interaction, user-friendly application and assured safe clinical
operation.
2.1.4 Final automated kV-MV-CBCT workflow
Novel combined kV-MV CBCT was set up as a simultaneous 90° kV and 90° MV
scan [18]. An overlap of additional +10° cone-angle had to be enclosed to enable full
reconstruction based on filtered backprojection (FDK approach) [40].
The kV contribution was set up with 100kVp, 0.1mAs per frame, an S20 collimator
with field size 27.67cm×27.67cm in isocenter, and 100° (90° + cone-angle) gantry
rotation. The gantry speed was in accelerated mode (1rpm), resulting in an image
rotation time of 15s. The acquired kV projections were post-processed within the
clinical XVI system (100 projections).
Since the MV linac and detector were not designed for continuous readout (the
vendor did not intend to provide MV-CBCT), tremendous effort had to be spent on
achieving continuous, low-dose MV imaging [18,99]. To avoid artifacts introduced
by the pulsing of the linac during panel readout, a dedicated FPGA-based hardware
was developed by a colleague in our research group. This hardware used the kV
detector pulses to trigger the MV-detector and to control the MV gating pulses. The
hardware guaranteed, that no linac pulse occurred during MV readout [99]. Since the
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readout rate of the MV detector is five times slower than the kV detector readout,
only every fifth kV-pulse could be used to trigger the MV detector readout, resulting
in five times less MV than kV projections. The MV contribution preset was set up as
follows: MV low-dose output of 4MU was distributed equally to the 19 acquired MV
projections per 90° rotation. The field size was 25cm×25cm in isocenter. Details
about the technical setup are listed in Table 2.1.
For the automated workflow, an application program was developed in a seperate
PhD study by a colleague in our research group [16], including all required steps in
generating a kV-MV CBCT volume. An article on the end-to-end test of finalized
kV-MV CBCT was recently submitted to a peer-reviewed journal.
Using a dedicated communication port (COM), the linac parameters were adjusted
to achieve low MV dose output (4MU distributed over 90°) and current gantry
angle position was read out continuously. MV projections were acquired and post-
processed according to standard procedures (such as gain, offset, bad pixel and
flexmap calibration). KV and MV volumes were reconstructed separately, using
our GPU accelerated reconstruction. The MV contribution was converted to kV-
equivalent scales by reconstruction-based histogram matching and both kV and
MV volumes were combined. Finally, the kV-MV 3D volume replaced the initial
kV-volume in the XVI registration tool for further routine processing [15,16].
2.2 Imaging modalities for the comparison studies
In this thesis, the novel ultra-fast imaging technique of combined kV-MV CBCT was
compared to several clinical and non-clinical alternative CBCT imaging techniques,
to evaluate clinical applicability and to point out expected benefits compared to
common clinically established techniques. The clinical and non-clinical CBCT
imaging techniques compared in this thesis are described in the following subsections.
Technical details are listed in Table 2.1.
Clinical kV-Chest1 CBCT
On LINAC1, the conventional kV-Chest1 CBCT preset was routinely used clinically
for lung SABR. The CBCT software version XVI v4.2.2 enabled kV radiation with a
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footswitch and 3D volume image acquisition in continuous mode only. The setup of
kV-Chest1 CBCT preset was 120kVp, 1mAs per frame, an M20 collimator with field
size 42.64cm× 27.67cm in isocenter, no additional filter (”F0”), and 360° gantry
rotation with rotation speed of 1/2rpm (Table 2.1). Image acquisition time was thus
2min.
Clinical kV-Chest2 CBCT
For the dosimetry test (2.3), the clinical preset kV-Chest2 of the latest available
CBCT software version was measured and evaluated for up-to-date comparison with
kV-MV. The software version XVI v5.0.2 was installed on LINAC2. The kV-Chest2
preset differed slightly from the kV-Chest1 preset of previous XVI version 4.2.2. A
bow-tie filter (”F1”) was applied and the nominal tube current (mA) and pulse
duration of exposure (ms) were reduced, as was thus the nominal dose. The x-ray
tube potential of 120kVp remained unchanged, as well as the collimator field size,
the detector position, rotation angle and speed. Acquisition time remained the
same (2min), however, beam interruptions were possible in case of DIBH treatment,
extending imaging time to 3−4min (Table 2.1).
Comparison of kV-MV CBCT with kV-Chest2 CBCT regarding image quality and
registration accuracy was not necessary, since image quality and registration accuracy
followed the same standard requirements as in previous versions. From XVI version
4.2 to 5.0, changes in reconstruction algorithm allowed reduction in mAs without
increasing noise [38]. The volume image acquisition could be interrupted, e.g. in case
of DIBH treatment. Image quality could be greatly improved for lung tumors scanned
in repeated breath-hold (DIBH), since residual motion artifacts were eliminated [21].
However, imaging time also increased considerably to 3−4min [19, 92].
kV180 CBCT
For correct reconstruction, filtered backprojection methods require a minimum scan
angle of 180° (plus 10° cone-angle in this study) with centered detector panel [40,87].
To compare with this minimum requirement setup of kV-CBCT, an additional non-
clinical kV180 CBCT preset was generated and applied on LINAC1. Tube settings
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were the same as in the kV contribution of novel kV-MV CBCT (100kVp, 1mAs per
frame). Rotation speed of 1rpm was generated and applied, leading to a reduced
imaging time of 30s. Considering breath-hold treatment, this fastest achievable
mono-energetic imaging method only requires one interruption for free breathing,
reducing imaging time to approximately 40s (Table 2.1).
MV180 CBCT
The development of the kV-MV synchronization hardware also allowed for creating an
MV180 CBCT preset on LINAC1, using the same low-dose MV beam characteristics
(8MU equally distributed over a 180° arc plus 10° cone-angle). Due to the triggered
linac pulse and the inability of the MV panel to constantly read out, the projections
could only be acquired every 5°, resulting in a dataset of 36 projections. The gantry
speed was 1rpm and the image acquisition time for breath-hold treatment with one
necessary free breathing phase was (30+10)s (Table 2.1).
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Preset kV-Chest1 CBCT kV-Chest2 CBCT kV180 CBCT MV180 CBCT kV-MV CBCT
Output characteristics 120kVp1mAs (25mA, 40ms) per frame
120kVp
0.4mAs (20mA, 20ms) per frame
100kVp
0.1mAs (10mA, 10ms) per frame
6MV linac
(8MU)
kV: 100kVp
0.1mAs (10mA, 10ms) per frame
MV: 6MV linac (4MU)
Acquisition length 360° 360° 180° + cone-angle(−90° to +100°)
180° + cone-angle
(−20° to +170°)
90° + cone-angle
(0° to +100°)
Panel position off-centered (M) off-centered (M) centered (S) centered (S) centered (S)
Filter, Collimator
(field size)
F0 (empty)
M20 (27.67cm×42.64cm)
F1 (bow-tie)
M20 (27.67cm×42.64cm)
F0 (empty)
S20 (27.67cm×27.67cm)
F0 (empty)
S20 (27.67cm×27.67cm)
kV: F0 (empty)
S20 (27.67cm×27.67cm)
MV: 25cm×25cm
Number of frames 650 660 190 36 kV: 100MV: 19
Imaging speed 1/2rpm 1/2rpm 1rpm 1rpm 1rpm
Acquisition time 2min minimum 2min minimum 30s minimum 30s 15s
Nominal dose 16mGy 5mGy 0.4mGy 8MU kV: 0.2mGyMV: 4MU
Table 2.1: Technical settings for different imaging presets, including kV-MV CBCT
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2.3 Dosimetric properties of kV-MV CBCT
In this section, imaging dose exposure to the patient was investigated and compared to
clinically established (kV-Chest1 and kV-Chest2 CBCT) as well as fastest-achievable
monoenergetic non-clinical imaging techniques (kV180 and MV180 CBCT). A standard
dose value for kV-MV CBCT preset was defined for future quality assurance (QA).
The phantom dose measurements were performed on two clinical linacs (LINAC1
and LINAC2).
All absorbed dose measurements were corrected following either the AAPM TG
protocol 61 [72] for kV-energy range, or the IAEA TPS 398 [56] for MV-range. For
both energy ranges, measurements were performed with two differently-calibrated
air-filled point-dose flexible cylindrical ionization chambers (Type 31013, 0.3cm3
sensitive volumes) and a UNIDOS E Universal dosemeter (all PTW Freiburg GmbH,
Freiburg, Germany). The first ionization chamber was calibrated in air kerma1
for kV-range (50kVp−150kVp), the second ionization chamber was calibrated on
absorbed-dose-to-water for 60-Cobalt (MV-range) [86]. The determination of beam
qualities and calibration factors for the dose measurements in both kV- and MV-
energy ranges are described in sections 2.3.1 and 2.3.2. To directly compare kV and
MV dose, the differences in relative biological effectiveness had to be taken into
account. A conversion factor for MV-dose to kV-equivalent relative biological dose is
presented and discussed in section 2.3.3. Section 2.3.4 describes the phantom setup
for (1) the patient simulation for exposed dose in an inhomogeneous thorax phantom
and (2) the determination of standard QA dose value, the CT dose index (CTDI).
2.3.1 kV beam quality and dose calculation
Following the task group (TG) protocol 61 from the American Association of Physi-
cists in Medicine (AAPM) [72], kV beam qualities for the applied beam setups were
characterized by measuring the half-value-layers (HVL) of Aluminium and calibration
factors were determined accordingly.
1kerma = kinetic energy released per unit mass
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kV beam quality - determination of HVL
The specification of beam quality for low-energy x-ray beams is typically given by
the peak voltage (kVp) and the half-value-layer (HVL). The HVL of an x-ray beam is
defined as the thickness of an absorber material that reduces the initial dose output
to one half (see equation 2.2) [49,62].
The setup for HVL measurements is leaned on the AAPM TG61 report [72]. A
self-made collimator with field size (5.5×5.5)cm2 in the isocenter was used to achieve
narrow-beam geometry. Through narrow-beam geometry, the exposure reading
should predominantly collect the transmitted photons; scattered radiation from
interaction with the absorber material is minimized by this setup [62, 97]. In our
setup, the x-ray source was positioned at 0° and the detector was moved out of the
field-of-view (FOV). A measurement stand on top of the treatment couch aligned both
the ionization chamber and the varying Aluminium absorbers with the center of the
FOV (see Figure 2.1a). To ensure full coverage of the sensitive volume and to avoid
anode heel effect, a planar image was acquired with XVI. After setup verification the
flat panel detector was retracted for protection. The source to surface distance (SSD)
was 100cm for the ionization chamber, the Aluminium absorbers were positioned
at SSD 50cm. The thickness of the attenuator varied from 0.01−10.31mm (Figure
2.1b), the purity of Aluminium was 99.9%.
The HVL was measured for three CBCT presets, kV-Chest1, kV-Chest2 and the kV
contribution of kV-MV CBCT with the same kVp and mAs settings as kV180 CBCT.
To achieve static irradiation from a fixed gantry angle the presets were modified
accordingly. Since the HVL measurements were relative measurements, the number
of acquired frames were non-relevant. 100 frames were acquired for kV-Chest1 and
kV-Chest2. Since the kV contribution of kV-MV had less dose output (smaller kVp,
smaller mAs), the number of frames were increased to 300. All preset collimators
were replaced with the narrow-beam collimator.
To determine the HVL for each beam setting, first, the initial dose output I0 with zero
absorber (free in air) had to be measured. In this experiment, I0 was measured four
times and the average value was considered as 100% relative dose output. Thereafter,
the thickness of the Aluminium absorbers was increased in different step sizes, and
dose output was measured. To increase the accuracy of the measurement in the
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(a) (b)
Figure 2.1: kV beam quality: (a) measurement setup for HVL determination, (b) Aluminium
absorbers (thickness 0.01−5.14mm).
I0/2 region the step size was reduced to 0.01mm which was the smallest available
Aluminium plate in this study.
Different approaches to determine HVL
To find the best mathematical description of the measured HVL data, different fit
functions were tested and compared:
Monoenergetic approach following Lambert-Beer-Law [49,62]: In literature,
the HVL is usually calculated under ideal conditions of a monoenergetic x-ray beam
and narrow-beam geometry, following the Lambert-Beer-Law:
I(x) = I0e−µx (2.1)
HV LLB =
ln2
µ
= 0.693
µ
for I(HV LLB) =
I0
2 , (2.2)
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with I0 the dose output (intensity of the beam) with no additional absorber material
in the beam (x= 0mm), x the thickness of the additional absorber material and µ
the linear attenuation coefficient. The linear attenuation coefficient µ depends on
the energy of the x-rays and the atomic number of the absorber material.
However, x-rays produced by an x-ray generator are polyenergetic. The x-ray energy
spectrum consists of a continuous energy distribution of bremsstrahlung photons
and discrete lines of characteristic radiation depending on target material, kVp
and beam filtration. Inherent beam filtration such as Aluminium filters in case of
diagnostic and superficial energy range (50−200keV) is used for beam hardening.
Low energy photons are absorbed by matter such as the patient’s body and thus do
not reach the imaging detector. They do not contribute to image quality but only
increase the radiation dose applied to the patient. Inherent filtration is added to
selectively remove low-energy photons, harden the beam and reduce imaging dose to
the patient [49,62]. In our experiment, the inherent filtration of the x-ray tube (at
100kVp) in XVI v4.2.2 is 6.3mm Aluminium equivalent [35], and 6.8mm Aluminium
plus 2mm Aluminium bow-tie filter thickness in the central beam for XVI v5.0.2 [37].
Quasi-monoenergetic approach: Two-Point-Interpolation method by Hill et
al. [50]: In many publications, the polyenergetic characteristics were simplified
and an effective monoenergetic energy with effective attenuation coefficient µeff was
assumed. If a log scale was used for the HVL measurement values, a linear decrease
was expected and HVL could be calculated with ”two-point linear interpolation”
[50,68,98]:
I(x) = I0e−µeffx = I0e−
∫ Emax
0 µ(E)dEx (2.3)
HV LLI = x1+(x2−x1)
 ln
(
I0
2
)
− lnI (x1)
lnI (x2)− lnI (x1)
 (2.4)
=
x1 ln
(2I(x2)
I0
)
−x2 ln
(2I(x1)
I0
)
ln
(
I(x2)
I(x1)
) with: x1 <HV L < x2
This approach however does not reflect reality. If an x-ray beam passes through
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material (e.g. absorber material), low energy photons are absorbed to a greater extend
and the beam becomes harder; the attenuation coefficient µeff is reduced. This effect
can be described with a beam-hardening coefficient η. With increasing absorber
thickness x, the rate of change in µ decreases, the slope of the logarithmic HVL
measurement curve decreases and is thus not linear anymore [62]. A useful measure
of the polyenergetic nature of x-ray beams is the homogeneity index HI = HV LQV L ,
calculating the ratio between the attenuator thickness for 50% I0 (HVL) and the
thickness for 25% I0 (quarter-value-layer QVL). Unfortunately, the homogeneity index
was not determined in our experiment because we did not have enough Aluminium
absorber plates to reach 25% of the initial dose exposure.
In literature several proposals to analyze the transmission characteristics in terms of
varying attenuation coefficient µ and beam-hardening coefficient η can be found.
Polyenergetic approach by Bjärngard/Shackford [14]: In 1994, Bjärngard and
Shackford analyzed the beam hardening effect in high-energy x-ray beams of 6MV
and 25MV. With increasing absorber thickness x, the beam became harder and
the attenuation coefficient µ decreased. The beam energy spectrum turned narrow
and the beam-hardening coefficient was reduced. They described the transmission
of the x-ray beam by an exponential function with a second-order polynominal in
thickness x. This equation for changing attenuation coefficient µ was determined
experimentally. The HVL could be calculated by solving:
I(x) = I0e−µx(1−ηx) = I0e−µx+µηx
2
(2.5)
HV LBS =
µ−
√
µ2−4µη ln(2)
2µη (2.6)
Polyenergetic approach by Yu et al. [106]: The study from Yu et al. was
based on the study of Bjärngard/Shackford [14], but they stated that the change rate
of attenuation coefficient µ also varies with absorber thickness. The incident beam
quality before beam-hardening was µ0. They concluded with equation 2.7 the larger
the absorber thickness, the slower the attenuation coefficient changes. Equation 2.8
could be used to calculate the HVL.
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I(x) = I0e
−µ0x
1+ηx (2.7)
HV LY U =
ln(2)
µ0−η ln(2) (2.8)
Polyenergetic approach #1 by Kleinschmidt [65]: In 1999, Kleinschmidt pub-
lished a comparison study between Bjärngard/Shackford [14] and Yu et al. [106] and
two alternatives suggested by him. He evaluated the different approaches for several
high-energy beams of 4−20MeV. His first alternative approach was a slight change
of the equation of Yu et al., taking the square of their denominator. The HVL could
be calculated by solving the quadratic equation:
I(x) = I0e
−µ0x
(1+ηx)2 (2.9)
HV LKS1 =
−(µ0−η ln(2))+
√
(µ0−η ln(2))2−4η2(ln(2))2
−2η2 ln(2) (2.10)
Polyenergetic approach #2 by Kleinschmidt [65]: Kleinschmidt stated, that
the previous equations (Bjärngard/Shackford and Yu et al.) were appropriate fits
for limited depths, however could lead to negative linear attenuation coefficients if
the absorber thickness was large enough. Since this is physically impossible, his
second alternative approach specified more conditions such as a minimum attenuation
coefficient µEmax and a third order polynomial of attenuator thickness dependency
(equation 2.11). To determine the HVLs of our study from this equation, Matlab
(MathWorks Inc, Natick, MA, USA) was used.
I(x) = I0e
−
(
µEmax+
µ0
1+η1x+η2x2
)
x = I0e−µEmaxxe
−µ0x
1+η1x+η2x2 (2.11)
HV LKS2 = determined with Matlab (3rd oder polynomial)
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kV dose correction factors
After calculating the HVL for each kV-imaging preset, the appropriate correction
factors were determined from the look-up-tables in AAPM TG61, following the
dosimetry formalism for tube voltages between 100 and 300kV [72]:
Dw = MNkPQ,chamPsheath
(µen
ρ
)water
air

water
(2.12)
with M = (Mraw−M0)PTPPionPpolPelec
The in-phantom formalism converted the air-kerma calibrated ionization chamber
measurement M [C] to absorbed-dose-to-water Dw [Gy]. The energy-specific air
kerma calibration factor Nk [Gy/C] was provided on the ionization chamber cali-
bration sheet provided by the accredited dosimetry calibration laboratory (PTW,
Freiburg, Germany), and was preset in the dosemeter. The background dosemeter
reading M0 was internally subtracted from the raw measurement data.
Prior to the dose measurements for our study, the ionization chamber had to be
corrected for daily atmospheric conditions, i.e. correction for air pressure P and
temperature T :
PTP =
P0(273.2+T )
P (273.2+T0)
with reference conditions P0 = 1013.25hPa and T0 = 20°C. This correction com-
pensated for possible increase of ionization from the reference measurement in the
ionization chamber, leading to higher measurement reading.
The correction factors for ion recombination Pion and electrode polarity effects Ppol
in the ionization chamber, and the correction factor Pelec for the dosemeter were
either considered by the calibration laboratory, or were negligibly small [56,66,72].
The following correction factors were directly dependent on the beam quality (HVL)
of the x-ray tube and were extracted from the look-up-tables in AAPM TG61 [72]:
• PQ,cham: overall chamber response correction factor, correcting for the changes
in beam quality between measurement and calibration conditions, for the
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chamber stem, and chamber displacements in the phantom.
• Psheath: waterproofing sheath correction factor, in case the ionization chamber
is not waterproof and requires a waterproof case.
•
[(
µen
ρ
)water
air
]
water
: average mass energy-absorption coefficient ratio in water
from as conversion factor from air kerma to dose-to-water.
2.3.2 MV beam quality and dose calculation
The determination of MV energy beam quality differed from the kV beam quality
procedure, because the MV beam was already hardened by heavy inherent filtration
of target and flattening filter. HVL measurements would not lead to significant
measurement alterations, therefore, the MV beam quality was specified by the peak
energy [62].
The most convenient method to determine the energy of the MV beam was to
measure the percent depth dose distribution (PDD) and put it in relation to reference
data, i.e. 60-Cobalt energy [49,62].
MV beam quality - determination of quality index Q
Following the technical report series (TPS) 398 of the International Atomic Energy
Agency (IAEA) [56] and the AAPM TG protocol 51 [3], the percentage depth dose
curve was measured in a water tank and the beam quality index Q of our clinical
6MV linac beam was determined (LINAC1).
The reference setup was source-to-surface distance SDD = 100cm, the field size was
10× 10cm2 in isocenter, and the PDD was acquired for a depth of 0− 30cm in a
water tank (IBA blue phantom, IBA Dosimetry, Schwarzenbruck, Germany) with a
scanning volume (L×W×H) of 48×48×41cm3 (see Figure 2.2). The ionization
chamber was positioned with central axis of the beam at the center of the cavity
volume.
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Figure 2.2: Measurement setup of the water tank to determine the beam quality for 6MV
linac (LINAC1).
MV dose correction factors
After acquisition of the percentage depth dose curve, percentage dose values of depths
20cm (M20) and 10cm (M10) were selected. The beam quality index was defined as:
Q= 1.2661M20
M10
−0.0595 (2.13)
The absorbed dose-to-water calculation for high energy beams (MV-range) followed
the formalism:
Dw = MND,wkQ (2.14)
with M = (Mraw−M0)PTPPionPpolPelec
Before the first measurement, the background dosemeter reading M0 was corrected
as well as the daily atmospheric conditions PTP . As an alternative to a pressure
and temperature correction PTP , one can perform a correction with the check source
method for the MV energy range. A reference check source reading of a radioactive
material (90Sr) was recorded on the ionization chamber calibration sheet from the
accredited dosimetry calibration laboratory (ADCL). The reference value of a given
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date for reference conditions, kp, was set relative to the current check source decay
km:
PTP =
kp
km
(2.15)
This correction factor, as well as the other factors Pion, Ppol and Pelec were considered
internally in the dosemeter (see correction factor description in section 2.3.1).
The absorbed dose-to-water calibration factor for the ionization chamber, ND,w, was
listed on the calibration sheet from the ADCL and was determined under reference
conditions for a 60Co beam.
The beam quality-dependent correction factor was the quality conversion factor kQ,
which converts the calibration factor of reference energy (60Co) to the energy of
beam quality Q [49,62]. A look-up-table is provided in IAEA TRS 398, listing kQ
factors for various ionization chamber types at different beam quality factors Q [56].
2.3.3 RBE - MV to kV dose conversion
The ICRP-60 and ICRP-103 reports [57, 58] suggest to keep a uniform value of
wR = 1 for the radiation weighting factor2 of all low-LET3-radiations such as x-rays,
electrons and gamma rays of all energies. However, several studies [51, 53, 83]
discovered an increase in biological effectiveness with decreasing photon energy.
These studies are either based on the epidemic data of the Hiroshima and Nagasaki
atomic bombs or on in vitro radio-biological measures, and show significant
differences in biological effectiveness for different energies.
The relative biological effectiveness (RBE) is defined as:
RBE = Dose from standard radiation to produce a given biological effectDose from test radiation to produce the same biological effect (2.16)
2The equivalent dose HT =R
∑
wRD is defined as the product of the (measured) absorbed dose
D and the radiation weighting factor wR.
3LET = dEdl : linear energy transfer, defined as the average energy loss dE by a particle of
specific energy in a distance dl [84].
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Standard radiation is commonly 60Co γ-rays (E = 1.17MeV and E = 1.33MeV) [84].
Specified biological effects range from cell killing to tissue damage, mutations and
other biological endpoints. Estimates of RBE range from 1−8 for different biological
endpoints [51, 53,83].
In IGRT, special consideration has to be taken into the increased risk of secondary
cancer after irradiation [44,48,64]. In the review of Nikjoo et al. [83], some studies
are presented in which the RBE between low- and high-energy photons was compared.
For the biological endpoint of neoplastic cell transformation, determined RBE values
range from 2−4. Hill et al. [51] and Borek et al. [26] determined an RBE=2 for low
vs. high photon energies.
In this dosimetry study, a conservative RBE ratio of 2 : 1 for kV vs. MV biological
effectiveness was chosen with regard to secondary cancer risk. Since the most common
clinical imaging technique is in kV-range, the MV-dose was converted to kV-equivalent
dose by reducing the MV dose by one half. In the case of RBE-consideration, the
dose unit was changed from Gray [Gy] to Gray-equivalent [GE].
2.3.4 Phantom setup
Dose measurement comparisons between kV-MV CBCT and other CBCT presets
were performed on two phantoms. To simulate patient imaging dose exposure, the
dose output in several regions of an inhomogeneous thorax phantom was measured
and evaluated. In a second measurement study, the kV-MV CBCT dose index was
determined and compared to other imaging techniques.
The dose measurements were performed for all presets, kV-Chest1, kV-Chest2, kV180,
MV180 and kV-MV CBCT. For kV-MV however, the dose measurements were per-
formed separately because of the different dose responses of kV- and MV-output.
Since the beam qualities of kV and MV differed, two differently calibrated ionization
chambers (as mentioned in section 2.3) had to be used, one for kV- and one for
MV-dose. This splitting of kV and MV dose components allowed separate evaluation
of the dose contributions. Relative biological effectiveness could be considered to
convert MV dose to kV-equivalent dose, making dose exposure results comparable to
other kV-only CBCTs. The splitting of the kV-MV image acquisition was straight
forward, similar to the kV180 and MV180 presets, just with only 100° rotation. In
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this study, no proper image acquisition was necessary, only the dose exposure was
recorded. To apply low-MV mode, the normal kV-MV mode was applied, except for
not starting the kV-exposure. The kV-software however had to be running, because
of the kV panel signal to trigger the low-dose MV linac output.
Inhomogeneous thorax phantom - patient simulation
The inhomogeneous thorax phantom (model 002LFC, CIRS, Norfolk, VA, USA)
consists of different materials according to the human thorax, i.e. mimicking two
lungs and a spinal cord. The diameter of the phantom was however smaller than a
body of a human adult (L×W×H: 43.2cm×38.1cm×22.9cm).
In our measurement setup, a target volume was defined in the lower left lung of the
phantom. This tumor was to be located in the isocenter (see Figure 2.3). Further
dose measurements were performed in the following representative beam positions of
the phantom:
1. tumor in lower left lung
2. left lung
3. right lung
4. upper periphery
5. spinal cord
6. body center
In order to spare the contralateral lung in analogy to a patient imaging procedure,
the kV-MV, kV180 and MV180 CBCT presets were designed to rotate only on the
side of the tumor location.
The MV contribution in the kV-MV CBCT scan was additionally simulated with the
Oncentra treatment planning system (Elekta Oncentra Masterplan OTP, Elekta AB,
Stockholm, Sweden) for 4MU per 100° arc.
CTDI Phantom
Following the quality assurance (QA) protocol of AAPM TG report 179 [12] and
AAPM TG report 75 [80], a standard dose value for regular QA was defined for novel
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(a)
1
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(b)
Figure 2.3: Setup of the inhomogeneous thorax phantom, (a) phantom position at LINAC1
(b) layout of measurement positions.
kV-MV CBCT.
In the last century, the CT dose index (CTDI), initially developed in 1981 as
convenient dose measure for diagnostic CT [89], was adapted for cone beam CT
dosimetry [39, 54, 94], although a much higher scatter contribution is present in
CBCT due to the broad geometry. Initially, the CTDI was measured with a 10cm
long ionization chamber, to collect the dose length product along the longitudinal
axis of a diagnostic slice-CT. A cone-beam, however, acquires a 3D volume within a
single rotation. Since common field of views of the CBCT are larger than 10cm, dose
equilibrium within the long ionization chamber cannot be guaranteed anymore, the
dose exposure could be underestimated. Therefore, Dixon et al. [34] suggested to use
a small point-dose ionization chamber to measure in the central beam of the CBCT.
Many CTDI determination and dose comparison studies between the different CBCT
presets of the two main linac manufacturers Elekta and Varian were published in
the last years [4, 28,54,63,94].
The CTDI measurements were performed in the CT body phantom (T40016, PTW,
Freiburg, Germany), made of polymethyl-mathacrylate (PMMA) with a density of
ρ = 1.19g/cm3. The diameter was 32cm, the axial length 15.2cm. As shown in
Figure 2.4, the phantom featured five cavities to sequentially insert the ionization
chamber: one center and four peripheral positions (at gantry angle 0°, 90°, 180°,
270°). Two point-dose ionization chambers (Type 31013, PTW Freiburg GmbH,
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(a)
cp,270°
p,0°
p,90°
p,180°
(b)
Figure 2.4: Setup of the CT dose body phantom, (a) phantom position at LINAC1 (b) layout
of measurement positions.
Freiburg, Germany) with individual calibration for kV and MV range were used
for the CTDI measurements (air kerma calibration for kV range (section 2.3.1) and
absorbed dose-to-water calibration for MV range (section 2.3.2)). An additional
halved dummy plug was placed into the cavities sequentially together with the
ionization chamber at axial midpoint of the phantom to prevent the air gap. The
phantom was aligned centrally to the isocenter. The weighted CTDI (CTDIw) was
calculated as follows [80]:
CTDIw =
1
3CTDIc+
2
3CTDIp , (2.17)
with CTDIc central dose
and CTDIp =
1
4
(
CTDIp,0°+CTDIp,90°+CTDIp,180°+CTDIp,270°
)
peripheral dose (averaged).
(2.18)
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2.4 Image Quality of kV-MV CBCT
A sufficient image quality is the prerequisite for precise image registration. In this
section, a brief evaluation of image resolution (section 2.4.1) and geometrical accuracy
(section 2.4.2) is provided.
Similar tests were already published previously with interim kV-MV CBCT data
[5,16,99]. However, in this thesis, image quality of latest kV-MV CBCT is compared
to clinical and non-clinical CBCT presets.
2.4.1 Spatial resolution - CatPhan phantom
Image quality is an important aspect of monthly quality assurance for clinical patient
position verification systems, i.e. CBCT [12]. The most common image quality QA
phantom is the CatPhan phantom (type CTP 503, The Phantom Laboratory, Salem,
NY, USA) [2], shown in Figure 2.5a. The manufacturer of LINAC1 and LINAC2
provides a non-clinical preset for image quality assurance, which is not clinically
enabled. This preset is using a high tube output, i.e. high mAs value, and thus high
imaging dose which is not justifiable for clinical application. Furthermore, image
reconstruction is performed with high resolution, leading to an image reconstruction
time too long for clinical application. Thus, these preset settings are exclusively
used to evaluate best achievable image quality in terms of spatial resolution, low
contrast visibility, uniformity and geometrical linearity, but do not represent the
clinical situation.
Spatial resolution is determined by scanning the high resolution module of the
CatPhan phantom. In this module, 21 line pair (lp) inserts, with increasing resolution
ranging from 1 to 21 lp/cm, are arranged on a circle. The high resolution is
evaluated visually [2]. In the customer acceptance test booklet provided by the
manufacturer [36], a minimum of 10 line pairs is the specification for the above-
mentioned image quality assurance preset, corresponding to a visible rod gap of
0.5mm (Figure 2.5b). This however is by far not achievable with clinical presets,
which have to balance between sufficient image quality and lowest reasonable imaging
dose.
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To put kV-MV CBCT spatial resolution into clinical context, a comparison had to
be performed with a clinical preset, i.e. kV-Chest1. The CatPhan phantom was
therefore scanned with the spatial resolution module in isocenter position. By visual
judgement, the highest number of visible line pair discrimination was determined.
(a) (b)
Figure 2.5: Image Resolution: (a) setup of CatPhan phantom, (b) axial slice CBCT scan
with the QA preset of high resolution module with 21 line pair per cm gauge (11 line pairs
visible).
2.4.2 Geometrical evaluation - inhomogeneous thorax phantom
In line with the following section about image registration (section 2.5), four different
custom-made tumor-mimicking shapes were placed in an inhomogeneous thorax
phantom. These inlays were sequentially aligned to isocenter position. The tumor-
shapes represented a ball, a cylinder with spikes and two star-shaped objects with
large and small body. The design of the tumor-mimicking shapes and the phantom
setup are shown in Figures 2.6a and 2.6b, respectively.
To determine geometrical accuracy of kV-MV CBCT, the diameter of each tumor-
mimicking shape (both body and spikes) was determined with Matlab and ImageJ
(http://imagej.nih.gov/ij, v1.48, National Institutes of Health, USA). To compare
kV-MV CBCT with clinical and non-clinical CBCT imaging, geometrical accuracy
was evaluated also for kV-Chest1, kV180 and MV180.
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(a) (b)
Figure 2.6: Registration accuracy study: (a) shapes of four tumor-mimicking inlays, (b)
experimental phantom setup with reference frame for optical tracking.
2.5 Registration Accuracy of kV-MV CBCT
The content of this section was recently accepted as a journal article in ”Strahlen-
therapie und Radioonkologie” 4 [7]. Some wording may be the same, some tables and
figures are directly taken from there.
In this section, image registration and positioning accuracy for kV-MV CBCT was
evaluated and compared with the conventional, clinically established technique kV-
Chest1 CBCT, as well as fastest achievable mono-energetic imaging with kV180 and
MV180 CBCT. The registration accuracy test was based on phantom studies, the
planning CT (Brilliance Big Bore Oncology, Philips, Hamburg, Germany) was used
as reference for registration. All measurements were performed on LINAC1.
In the following subsections, the phantom setup, the realization of high-precision
positioning accuracy, the different registration methods (including the development
of an own automatic registration framework), the measurement workflow and the
evaluation methods are described.
4The final publication is available at Springer via http://dx.doi.org/ [10.1007/s00066-016-0947-
2].
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2.5.1 Registration accuracy phantom setup
Four different custom-made tumor-mimicking shapes were placed in an inhomoge-
neous thorax phantom. The tumor-shapes represented a ball (φ= 15mm), a cylinder
(φ= 6mm, length = 20mm) with spikes (3mm) and two star-shaped objects with
large (φ= 15mm) and small (φ= 10mm) body. The inlays were positioned in the
lower left lung of the thorax phantom sequentially. The phantom setup was the same
as for the geometrical accuracy test in section 2.4.2 (image quality), see Figure 2.6a.
Each tumor-shape was marked at isocenter in the planning CT and set as reference
CT in the XVI software registration tool.
In total, 10 different shifts were pre-selected randomly based on a Gaussian dis-
tribution around the isocenter position (positive on right hand side) and applied
in right-left (RL), anterior-posterior (AP) and cranio-caudal (CC) directions. The
standard deviation of the Gaussian was chosen to be 1cm in all room directions
(Table 2.2).
Room direction Isocenter shift [mm]#1 #2 #3 #4 #5 #6 #7 #8 #9 #10
left → right 5.0 −5.7 −10.6 −12.9 −2.9 1.7 −2.7 −6.4 −4.8 −10.2
posterior → anterior 3.2 −3.5 −11.6 11.0 −6.4 17.7 −8.4 13.1 −4.2 −12.8
caudal → cranial 7.6 3.5 −8.6 9.6 3.9 11.8 −1.6 1.2 14.7 −12.7
Table 2.2: Gaussian distributed isocenter shifts (standard deviation 1mm) for registration
study.
2.5.2 Positioning Accuracy
Optical tracking was used to overcome the limitation of ±0.5mm registration accu-
racy of the clinical treatment couch (Elekta Precise with couchtop iBeam evo). The
software iGuide (v1.0, Medical Intelligence, Schwabmünchen, Germany), in combi-
nation with the corresponding reference frame and its reflective infrared markers
detectable by an NDI Polaris camera (see Figure 2.6b), controlled the sub-mm shift
of the couch position. The specification of the calibrated 3D tracking system is
0.35mm RMS [101], however, in this measurement setup, iGuide and optical tracking
were used in relative mode only. The frame was not calibrated to isocenter position,
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its reflective infrared markers were merely used as a more accurate relative step
width controller (0.1mm step width) compared to standard in-room monitor (1mm).
2.5.3 Registration Methods
To evaluate and compare the positioning accuracy of different CBCT imaging tech-
niques, each dataset was registered with the corresponding planning CT. Registration
was performed oﬄine, since this study focused on the comparison of registration
accuracy of differently acquired CBCT volumes, not the precision of couch movement.
Thus, executing the registered shift back to the original phantom isocenter was not
necessary. The individual matching results were compared to the a priori known and
applied random isocenter shifts (see Table 2.2).
Three different registration methods were applied and evaluated, as described in the
following.
(I) Manual registration in XVI software
Manual soft tissue matching is routinely used in our clinic and was applied by three
experienced physicians to perform registrations. The order of the volumes was mixed
when presented to the clinicians such that objectiveness was assured.
(II) Automatic registration in XVI software
Automatic registration provided in XVI software is based on a voxel greyscale
intensity value algorithm [52]. An alignment box was assigned around the tumor
only, obtaining objective evaluation of local tumor shape contrast and precise tumor
registration. In the algorithm, only this alignment box was then taken into account
for registration. Since the tumor alignment box was smaller than the distance of
most applied isocenter shifts, gross phantom registration had to be performed prior
to alignment box setting and following automatic tumor registration. The initial
gross alignment was performed manually. The correction reference point was the
isocenter position of the planning CT.
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(III) Objective automatic registration with self-developed software (in-house)
Since automatic registration in XVI was depending on the initial manual setting of
the alignment box, an objective automatic registration had to be developed. For this
specific task, there was no software available. Therefore, a framework was developed
for automatic registration with Matlab. The rigid intensity-based registration toolkit
was used, the similarity metric was based on mutual information [31].
For a given isocenter shift, all CBCT datasets were cropped to the same region of
interest (tumor inlays), similar to the alignment box in XVI. However, the Matlab
framework achieved the same initial situation for the starting point of registration
for all different imaging techniques on each phantom isocenter shift. Assuring this
same region of interest was the prerequisite for proper objective comparison study
between different imaging techniques. Thus, each phantom shift was determined by
registering the CBCT volume center to the planning CT isocenter.
In the following subsections, the self-developed automatic registration framework is
explained in detail, the main Matlab code is provided in Appendix A.2. Since the
framework behaved in the same manner for all combinations of CBCT on planning CT
registration, the different imaging techniques (kV-Chest1, kV180, MV180 and kV-MV
CBCT) are hereby entitled as CBCT or the moving volume. The fixed volume is
the planning CT (pCT). To stay conform with the recently accepted publication [7],
this self-developed framework is subsequently captioned as ”automatic registration
(in-house)”.
Data handling in Matlab
The 3D volume data of the different imaging techniques had to be imported into
Matlab and prepared for precise cropping to the alignment box around tumor only.
• The planning CTs of the four tumor-mimicking shapes were imported as
DICOM-files. Since the field of view was adapted manually during the CT
scan, the pixel size and number of slices varied for each 3D planning CT
volume (pCT). The details of the geometric parameters are listed in Table
2.3. Before CT volume data acquisition, the inhomogeneous thorax phantom
was pre-positioned such that each tumor-mimicking shape was roughly in the
36
2.5 Registration Accuracy of kV-MV CBCT
center of the chosen field of view. After the CT scan, the precise isocenter
was marked manually in the center of each tumor-mimicking shape, which
could slightly differ from the center of the 3D volume data set. The isocenter
coordinates were stored in the DICOM RTPlan-file of each dataset. Since the
coordinate system of the planning CT differed from the Matlab matrix data
handling, the isocenter coordinates had to be converted to Matlab-conform
spatial system (world coordinates in mm). In Matlab, the coordinate system
origin is in the upper left back of the 3D volume dataset. The planning
CT isocenter coordinates were thus converted by subtracting the isocenter
coordinates provided in DICOM RTPlan5 from the upper left corner of the
backmost slice6. Isocenter position was verified visually by comparing the
zoomed marked position in Matlab with the zoomed position in planning CT
software according to inlay-shape and grey-value pixel.
• The kV-Chest1 CBCT volumes were also imported and sorted as DICOM-files.
The center of each volume dataset was the center of rotation, i.e. the kV and
MV isocenter coincidence at the linac. Thus the tumor-mimicking shape was
off-centered for applied isocenter shifts.
• The volume data of kV180, MV180 and kV-MV were reconstructed by in-house
developed reconstruction software [18], as mentioned in section 2.1. Each
data set was stored as raw 3D volume and had to be imported and reordered
in Matlab to be conform with the coordinate system of both planning CT
and CBCT. Detailed volume data size is given in Table 2.3. Like for clinical
kV-Chest1 CBCT, the center of each 3D volume dataset was the center of
gantry rotation, i.e. the machine isocenter.
To receive the isocenter shift vector in mm and to handle different spatial resolutions
of CT and CBCT datasets, the intrinsic coordinates of each voxel were allocated to
a world coordinate system with the function imref3D in Matlab.
For example, the planning CT of the ball-shaped tumor-inlay had an image size
of 512× 512× 92, with a pixel size (X- and Y-direction per Matlab definition)
of 0.8809mm and a slice thickness of 1mm (Z-direction). The intrinsic limits in
Matlab, i.e. the voxel corners in all extremes, were thus [0.5 512.5] in X- and
5RTPlan.BeamSequence...ControlPointSequence.Item_1.IsocenterPosition
6info_pCT.ImagePositionPatient
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Y-direction, and [0.5 92.5] in Z-direction. The world coordinate limits however
were [0.4404 451.4404] in X- and Y-direction, and [0.5 92.5] in Z-direction, thus
respectively considering the pixel size and slice thickness.
3D volume size pixel size slice thickness
pCT (Ball shape) 512×512×92 0.8809mm 1mm
pCT (Cylinder) 512×512×98 0.8574mm 1mm
pCT (Star10) 512×512×87 0.8514mm 1mm
pCT (Star15) 512×512×114 0.8652mm 1mm
kV-Chest1 CBCT 410×410×264 1mm 1mm
kV180,
512×512×512 0.5mm 0.5mmMV180 and
kV-MV CBCT
Table 2.3: Pixel sizes, slice thickness and 3D volume sizes for all imaging methods.
Application of rigid intensity-based registration toolkit
The goal of the developed framework for rigid translational intensitiy-based registra-
tion was to determine the isocenter-shift vector of CBCT to pCT, TCBCT→pCT , as
illustrated in Figure 2.7. The developed framework, as applied to all 160 datasets,
was covered by five steps:
1. Definition of alignment box around tumor-shape for both pCT and CBCT;
determination of transformation vectors tpCT,ab and tCBCT,ab
2. Registration of CBCT alignment box to pCT alignment box, determination of
registration transformation vector (alignment box) TCBCT,ab→pCT,ab
3. Back-transformation of TCBCT,ab→pCT,ab result from the alignment box to
the full 3D volume of both pCT and CBCT, determination of registration
transformation vector (full 3D volume) TCBCT→pCT
4. Calculation of final registered isocenter-shift from the center of CBCT volume
to the isocenter position in pCT; transformation of isocenter-shift from Matlab
to linac coordinate system
5. Visualization of registered pCT and CBCT volumes for qualitative evaluation
In the following, these steps are described in detail.
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pCT – fixed volume
(pixel size: pxpCT, slice thickness: stpCT)
CBCT – moving volume
(pixel size: pxCBCT, slice thickness: stCBCT)
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Figure 2.7: Illustration of registration transformation vector from CBCT to pCT for both
full 3D volume and alignment box.
1. Alignment box: All datasets (pCT and CBCT) were cropped to an alignment
box around the tumor-shapes only. The size of the box was 36×36×36 pixels; in
case of the cylinder-shaped tumor-inlay the z-direction (craniocaudal) was increased
to 52 pixels to cover the whole inlay. The tumor-position in the pCT was given by
the isocenter coordinates. The data voxels covering the alignment box were thus
determined by definition of isocenter position being the center of alignment box
pCT. Since the applied isocenter shifts were known, this a priori information and
the knowledge of CBCT pixel size helped to assume the rough location of each
tumor-shape in each CBCT dataset. This calculated voxel shift was set as the center
of alignment box for CBCT. The transformation vectors from full 3D volume to
alignment box for both fixed pCT (tpCT,ab) and moving CBCT (tCBCT,ab) in world
coordinates were:
tpCT,ab =

(xpCT −1)pspCT
(ypCT −1)pspCT
(zpCT −1)stpCT
 , tCBCT,ab =

(xCBCT −1)psCBCT
(yCBCT −1)psCBCT
(zCBCT −1)stCBCT
 (2.19)
with (xpCT |ypCT |zpCT ) and (xCBCT |yCBCT |zCBCT ) the coordinates of the upper left
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back corner of the alignment box of both pCT and CBCT (see Figure 2.7), and
pspCT , psCBCT , stpCT and stCBCT the pixel size and slice thickness of pCT and
CBCT, respectively.
2. Rigid translational registration with Matlab toolkit: The intensity-based
registration toolkit provided by Matlab was adapted to our demands. Rigid registra-
tion in translational directions was sufficient, since the treatment couch was unable
to correct for rotational or deformed registration detection errors. The function
imregtform determined the registration transformation matrix TCBCT,ab→pCT,ab
between the alignment boxes of fixed pCT volume and moving CBCT volume in
world coordinates (considering different spatial resolutions). The voxels of the CBCT
were mapped to the pCT volume, i.e. the registered CBCT volume adapted to the
world coordinate system of pCT. The optimizer and metric were previously defined
with the function imregconfig. The optimizers initial radius was set to 0.004, the
maximum number of iterations was chosen to be 300. The measure of similarity
(metric) was multi-modal Mutual Information [31], since the brightness ranges of the
CT and CBCT were not the same. An illustration of the alignment boxes and the
transformation vectors is given in Figure 2.7.
3. Back-transformation to full 3D volume after registration: The registra-
tion transformation vector TCBCT→pCT of the full 3D volumes of pCT and CBCT
was calculated as follows:
TCBCT→pCT = tpCT,ab+TCBCT,ab→pCT,ab− tCBCT,ab (2.20)
Figure 2.7 demonstrates this relation between the different transformation vectors:
The difference of both alignment box transformation vectors had to be added to the
registration transformation vector between the two alignment boxes, determined by
the provided Matlab toolkit.
4. Calculation of final registered isocenter-shift in linac coordinates: The
applied isocenter shift between tumor in pCT and tumor in initial CBCT was desired
to be validated by automatic registration. The function transformPointsForward
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applied the registered translation vector TCBCT→pCT on a point in the initial CBCT
to determine where that point was found after registration in the coordinate system of
the fixed pCT volume. The center coordinates of initial CBCT volume were required
to be mapped as coordinates after CBCT registration in the coordinate system of
pCT (world coordinates, pixel size, slice thickness and volume size of pCT). Figure
2.8 illustrates the center coordinates before and after registration. The resulting
final isocenter shift was then the difference between the initial center of rotation and
the isocenter coordinate of pCT. After conversion from Matlab to linac coordinate
system, the isocenter shift determined by image registration should ideally be in
accordance with the initially applied isocenter shift as listed in Table 2.2.
pCT – fixed volume CBCT – moving volume CBCT registered on pCT
(translation and scaling) 
ISOpCT
ISOpCT centerCBCT
centerCBCT
Figure 2.8: Illustration of point forward transformation to map the center of CBCT in the
registered CBCT with the coordinate system of the planning CT.
5. Visualization of registered pCT and CBCT To visualize the registration
result in both full 3D volume and alignment box, the transformation matrices
TCBCT→pCT and TCBCT,ab→pCT,ab, respectively, were applied linearly on the full
and cropped CBCT (moving volume). This was achieved by the function imwarp
considering the spatial information of the registered volume, which was scaled to
the spatial information of the fixed pCT volume. The function imshowpair allowed
overlapping visualization of single axial slices from both planning CT (green = fixed
volume) and CBCT (magenta = moving volume) before and after registration was
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possible.
Script for automatic registration of all acquired 3D volumes
A framework was developed for fully automatic registration with the Matlab toolkit
for all acquired 3D CBCT volumes (kV-Chest1, kV180, MV180 and kV-MV) for all four
tumor-mimicking phantom shapes with according planning CT. This script directly
wrote the resulting isocenter shifts (in consideration of differences in coordinate
systems of linac and Matlab software) to an excel sheet, which was thereafter used
for automatic evaluation (see section 2.5.5).
2.5.4 Measurement workflow of phantom shifts
For each tumor shape, the workflow was divided into two steps:
• Isocenter verification:
The inhomogeneous thorax phantom was aligned to the markers using room
lasers. A clinically approved kV-CBCT scan was performed and registered to
the reference CT using XVI automatic matching (grey value method). Emerging
phantom tilts were corrected and the scan was repeated until no rotational
errors were detectable anymore. The remaining translational setup error was
corrected using iGuide. The tumor was then in accurate isocenter position
(±0.05mm) and the couch vector was reset to zero.
• Isocenter shift:
Based on this initial zero position, the 10 pre-defined translational shifts (Table
2.2) were applied sequentially. The iGuide software was used to monitor the
relative shift of each phantom position and CBCT scans with kV180, MV180
and kV-MV imaging methods were acquired. The procedure was repeated for
each tumor shape, including the initial isocenter verification. Thus, 4 times 30
datasets were collected.
To provide comparison with a clinically used preset, the panel position and the gantry
speed were changed to kV-Chest1 CBCT setup and the procedure was repeated for
all tumor-mimicking shapes (4 times 10 shifts).
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2.5.5 Evaluation methods
The detection error was the difference between registration result and original couch
shift (Table 2.2). 36 datasets were generated, consisting of four imaging techniques,
three registration methods and three translational shift directions. For automatic
registrations, each dataset consisted of 40 detection error values (four tumor-shapes
with 10 shifts each). Manual registration was performed by three physicians, resulting
in 120 values each. Mean and standard deviation as well as maximum and minimum
detection error were calculated.
Paired difference statistical test was performed between all imaging techniques.
Furthermore, the same test was applied to evaluate whether there were significant
differences between the three registration methods. In both cases, null hypothesis
indicated zero mean of the difference between the paired samples. A significance
level of 5% was chosen. To consider normal or non-normal distributed data sets for
calculation of p−value, the Wilcoxon Signed Rank Test [100] was chosen instead of
more common Student’s t-test.
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Towards clinical implementation of novel combined kV-MV CBCT, the properties
had to be distinguished and analyzed. For each aspect, comparison studies with
clinically established CBCT methods were performed. In section 3.1, the results for
the dosimetric aspects of the kV-MV approach are presented. The image quality is
quantified in section 3.2, and the results of the registration accuracy study of kV-MV
CBCT vs. other clinical CBCT methods is presented in section 3.3.
3.1 Dosimetric properties of kV-MV CBCT
The dose exposure of kV-MV CBCT was measured and compared to other clinical
and non-clinical imaging methods. For proper dose determination and evaluation of
different imaging modalities, such as kV-dose output at two different x-ray sources
and MV-dose output, the two different ionization chambers for absorbed dose mea-
surements were calibrated. Therefore, beam qualities of kV and MV energies were
determined (section 3.1.1). To facilitate the comparison of dose exposure of different
imaging modalities, the MV-dose was converted to kV-equivalent dose by considering
the different relative biological effectiveness between kV and MV. A conservative
ratio of 2 vs. 1 for kV vs. MV, respectively, was selected [26, 51], i.e. energy
independent comparison was possible. To simulate a real patient, the dose exposures
at different positions in an inhomogeneous thorax phantom were measured (section
3.1.2). Furthermore, the CT dose index was determined for future QA purposes
(section 3.1.3).
45
3 Results
3.1.1 kV and MV beam quality and dose calibration
Following the AAPM TG protocol 61 (kV-energy) [72] and the IAEA TRS 398 and
AAPM TG protocol 51 (MV-energy) [3, 56], the beam qualities and corresponding
calibration factors for dose measurements were determined for all presets applied in
this study.
kV beam quality and calibration factors
To determine proper half-value-layers (HVL) for kV-Chest1, kV-Chest2 and kV
contribution of kV-MV CBCT, our measured values for HVL (see Table A.1 in
Appendix) were compared with six approaches (see details in section 2.3.1):
• Monoenergetic approach following Lambert-Beer-Law [49,62]
• Quasi-monoenergetic approach: Two-Point-Interpolation method by Hill et
al. [50]
• Polyenergetic approach by Bjärngard/Shackford [14]
• Polyenergetic approach by Yu et al. [106]
• Polyenergetic approach #1 by Kleinschmidt [65]
• Polyenergetic approach #2 by Kleinschmidt [65]
In Table 3.1 and Figure 3.1, the different calculation results of HVLs are listed and
compared to our measured half-value-layers for all kV-presets. As can be seen in
Figure 3.1, the approach from Bjärngard/Shackford [14] had the best fit to our
measurement data. The goodness of the fit, represented by the R2 value, ranged
from 0.9988−0.9997. Even though their study was performed on high-energy beams
(MV-range), the principle of beam hardening stays the same.
Theoretically, the approach #2 from Klevenhagen [66] seemed to be convincing
from the physics point of view, however the fit function did not match at all with
our measurement data. More studies on the aspect of finding a proper, physically
reasonable fit function would be an interesting research topic for the future.
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Method: kV-Chest1 kV-Chest2
kV-MV
(kV part)
[mm] [mm] [mm]
HVL measurement 7.15 7.65 5.64
interpolation (Hill et al.) 6.39 7.49 5.19
monoenergetic (Lambert-Beer) 7.03 7.61 5.67
polyenergetic (Bjärngard/ Shackford) 7.01 7.63 5.57
polyenergetic (Yu et al.) 7.03 7.64 5.58
polyenergetic (Kleinschmidt #1) 6.45 7.23 5.23
polyenergetic (Kleinschmidt #2) 7.08 7.65 5.65
Table 3.1: Half-Value-Layers of kV-Chest1, kV-Chest2 and kV contribution of kV-MV CBCT:
measured and calculated values with different fit functions.
The final HVLs determined from the Bjärngard/Shackford fit function were 7.01mmAl
for kV-Chest1, 7.63mmAl for kV-Chest2, and 5.57mmAl for kV180 and kV contribu-
tion kV-MV CBCT.
These fit function results (HV LBS) not only match with our direct measurement
results within 2% maximum difference, but the resulting HVLs were also consistent
with common measurement values for comparable or the same kV settings.
Textbooks mention a typical range of (1− 8)mmAl for diagnostic and superficial
x-rays [49,62]. The AAPM TG61 report [72] gives a HVL range of (0.15−6.83)mmAl
for 100kVp and (1.48−8.33)mmAl for 120kVp. Beam quality changes with age of
the x-ray tube, since the target material roughens with time.
Similar measurements were presented by Song et al. [94]; they used a comparable
setup and found HVLs of 6mmAl for 100kV and 7mmAl for 120kV, resulting in
a 7% difference (kV180 and kV contribution of kV-MV CBCT) and full agreement
(kV-Chest1) to our presets, respectively.
Hyer et al. [55] was in 5% difference agreement with HVLHead = 5.9mmAl and our
kV180 CBCT preset. Their Chest-preset had a higher current than ours and thus
their HVLChest was not comparable to both our kV-Chest presets.
The kV correction factors of the dosimetry formalism in equation 2.12, that were
directly beam quality dependent, were extracted from the look-up-tables provided in
AAPM TG report 61 [72].
The chamber response correction factor PQ,cham could not directly be selected be-
cause our ionization chamber was not listed. However, it is recommended [72] to
choose a value from a similar, listed chamber. Thus, we chose the correction factors
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Figure 3.1: Determination of best fit for Half-Value-Layers of kV-Chest1, kV-Chest2 and kV
contribution of kV-MV CBCT, which had the same settings as kV180.
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of Farmer chamber PTW Type 30001. With two-point-interpolation1, the corre-
sponding correction factors to our HVLs were extracted.
The sheath correction factor was Psheath = 1, since our ionization chamber was
waterproof, i.e. did not require an additional waterproof case. Furthermore, our
measurements were not performed in water.
The conversion factor from air kerma to dose-to-water
[(
µen
ρ
)water
air
]
water
was di-
rectly taken from the look-up-table. The exact conversion factor for each HVL was
determined by two-point-linear interpolation.
The final absolute dose correction factors for kV-energy range are listed in Table 3.2,
separated for all kV-CBCT presets applied in this study.
kV-contribution of
kV-Chest1 kV-Chest2 kV-MV, and
CBCT CBCT kV180 CBCT
HVL 7.01mmAl 7.63mmAl 5.57mmAl
PQ,cham 1.022 1.023 1.019
Psheath 1.000 1.000 1.000[(
µen
ρ
)water
air
]
water
1.0394 1.0417 1.0346
Nk 8.757 ·107Gy/C
Table 3.2: Absolute dose correction factors for kV-energy range for all applied kV-imaging
methods, based on AAPM TG report 61.
Other uncertainties primarily to the fact that not all phantoms consisted of water-
equivalent materials were not considered. Following the AAPM TG report 61, the
overall measurement uncertainty was 4.7%, including different density phantom
material.
MV beam quality and calibration factors
Following the reference setup in IAEA TRS 398 [56], the beam quality index Q was
determined by measuring the percentage depth dose curve of LINAC1 and extracting
the percentage dose values for measurement depths 20cm and 10cm:
Q= 1.2661 ·M20
M10
−0.0595 = 1.2661 · 40.067.9 −0.0595 = 0.6858 (3.1)
1Two-point-interpolation mode to determine value y from corresponding value x with two
neighbour points (x1,y1) and (x2,y2) : y = y1+(y2−y1) x−x1x2−x1 , with x1 < x < x2.
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Figure 3.2 shows the percentage depth dose curve. The quality conversion factor kQ
was extracted from the corresponding look-up-tables for different ionization chambers
and beam quality factors in IAEA TRS 398. Two-point-interpolation was applied to
calculate the correct quality conversion factor. Table 3.3 lists the required calibration
factor results.
0 25 50 75 100 125 150 175 200 225 250 275 300
depth [mm]
0
10
20
30
40
50
60
70
80
90
100
do
se
 [%
]
  M10 = 67.9%
  M20 = 40.0%
Figure 3.2: Percentage depth dose curve of
6MV linac (LINAC1) for determination of beam
quality correction factor.
Correction factors
for MV energy range
Q 0.6858
kQ 0.9894
ND,w 1 ·108Gy/C
Table 3.3: Absolute dose correction fac-
tors for MV-energy range for all applied
MV-imaging methods, based on IAEA
TRS 398.
Dose calibration was thus provided for the MV contribution of kV-MV CBCT and
the MV180 CBCT preset.
3.1.2 Inhomogeneous thorax phantom - patient simulation
The dose exposure to an inhomogeneous thorax phantom was measured for different
imaging methods. To simulate a patient case, a target volume was defined in the lower
left lung of the phantom. This tumor-position was aligned to the isocenter. Other
representative dose measures were performed in the organs at risk, such as the left
and right lung, the spinal cord, the body center, and the upper periphery to evaluate
skin dose. Figure 3.3a shows the phantom and the evaluated positions close-up.
Column 3 in Table 3.4 shows the corrected absolute dose output for the various
locations (serially numbered) and imaging methods. The dose measurements of
kV-MV CBCT were performed separately, because the dose responses of kV and MV
behaved differently. Furthermore, the single dose contributions could be distinguished
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and the different relative biological effectiveness could be considered, enabling proper
dose comparison in kV range. For a complete overview, the kV and MV contributions
to the kV-MV dose output are listed in columns 6 and 4, respectively. The MV dose
measurement results of MV180 CBCT and the MV contribution of kV-MV CBCT
were converted to kV-equivalent dose by halving the MV dose value2 according to
the RBE =MV/kV = 2. This kV-equivalent MV dose output is listed in column 5 of
Table 3.4. The final absorbed dose of kV-MV CBCT in column 3 is the sum of the
kV contribution and the kV-equivalent MV contribution; the unit is thus [GE].
(a) (b)
Figure 3.3: Setup of (a) inhomogeneous thorax phantom, (b) CT dose phantom for dosimetry
study.
Dose comparison of kV-MV imaging vs. conventional CBCT
Table 3.5 gives an overview of the ratios between kV-Chest1 and the other imaging
techniques with kV-Chest1 set as fixed reference value. Table 3.6 demonstrates the
ratios if kV-Chest2 is the reference dose output.
Among each other, the two clinical presets, kV-Chest1 and novel kV-Chest2 differ
mainly in the applied nominal tube current (mA) and pulse duration (ms), i.e. 1mAs
and 0.4mAs, respectively. Furthermore, the bow-tie filter in kV-Chest2 CBCT also
reduces imaging dose [73]. The nominal doses provided by the manufacturer are
16mGy and 5mGy, respectively. The kV-Chest1 preset resulted in an absolute dose
2The unit of kV-equivalent MV dose is Gray-equivalent [GE].
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Position CBCT Final MV part MV part kV partabsorbed dose (kV-equivalent)
kV-Chest1 31.26mGy
1: tumor- kV-Chest2 9.10mGy
lower left kV180 0.62mGy
lung MV180 40.85mGE 81.70mGy 40.85mGE
kV-MV 20.51mGE 40.26mGy 20.13mGE 0.38mGy
kV-Chest1 32.00mGy
2: left kV-Chest2 9.13mGy
lung kV180 0.47mGy
MV180 41.17mGE 82.34mGy 41.17mGE
kV-MV 22.88mGE 45.10mGy 22.55mGE 0.33mGy
kV-Chest1 22.85mGy
3: right kV-Chest2 5.22mGy
lung kV180 0.27mGy
MV180 14.06mGE 28.12mGy 14.06mGE
kV-MV 6.60mGE 13.02mGy 6.51mGE 0.09mGy
kV-Chest1 23.06mGy
4: upper kV-Chest2 6.21mGy
periphery kV180 0.25mGy
MV180 34.35mGE 68.71mGy 34.35mGE
kV-MV 19.10mGE 37.95mGy 18.98mGE 0.13mGy
kV-Chest1 16.45mGy
5: spinal kV-Chest2 4.62mGy
cord kV180 0.36mGy
MV180 33.74mGE 67.49mGy 33.74mGE
kV-MV 15.12mGE 29.82mGy 14.91mGE 0.20mGy
kV-Chest1 21.54mGy
6: body kV-Chest2 5.96mGy
center kV180 0.30mGy
MV180 33.05mGE 66.10mGy 33.05mGE
kV-MV 17.57mGE 34.83mGy 17.41mGE 0.16mGy
Table 3.4: Determination of absorbed dose for different imaging techniques in the inhomoge-
neous thorax phantom (GE: Gray-equivalent with RBE = 2 for kV-dose distribution).
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of 31.26mGy in the tumor and 22.85mGy in the contralateral lung. For kV-Chest2,
these dose values were reduced by a factor of 3-4, resulting in 9.10mGy for the tumor
region and 5.22mGy for the organ at risk. Dose output was slightly inhomogeneously
distributed around the phantom due to the fact that the phantom was positioned
off-centered. The smallest dose was detected in the body center.
The kV180 CBCT had remarkably lower dose output; measured doses were maximum
2−8% of the corresponding dose values in kV-Chest1 and kV-Chest2. Dose output
was so negligibly small compared to the others, that the asymmetric dose distribution
was barely noticed.
Absorbed doses of MV180 were maximum twice as large as the widely-used kV-Chest1
CBCT preset. Due to the asymmetric dose distribution and the gantry angle moving
from −20° to +170°, the maximum dose occured in the left lung with 41.17mGE.
The tumor dose was 40.85mGE. The smallest dose was measured in the contralateral
lung: With 14.06mGE this dose was 40% lower than in case of the clinical preset.
The largest difference to the corresponding value of the clinical preset kV-Chest1 was
in the body center. This can be explained by the shifted dose maximum of the MV
beam compared to the kV beam. Natural implications are the increasing doses with
a ratio of 2.7 and 7.3% compared to the latest available kV-Chest1 CBCT.
Novel kV-MV CBCT dose outputs lie in between the dose outputs of both clinical
presets. Maximum dose of kV-MV CBCT was 22.88mGE at the left lung position.
Minimum dose of 6.60mGE was exposed to the contralateral lung. This was due to
asymmetric dose distribution, organs at risk could be spared. At the tumor position,
dose output of the kV-MV approach was 20.5mGE, i.e. it was 35% smaller than
the kV-Chest1 output and 2.2 times higher than the kV-Chest2 output. The largest
difference of 3.3 times the dose output of the kV-Chest2 CBCT appeared at the
position of body center. Compared to the kV-Chest1 CBCT, however, kV-MV dose
output was still 8% lower.
Comparison of MV dose measured vs. calculated (TPS)
To demonstrate the asymmetric dose distribution of kV-MV CBCT, the MV contri-
bution was simulated in the Oncentra treatment planning system. The axial dose
distribution of 4MU equally distributed over a 100° is shown in Figure 3.4. The
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Position kV-Chest1 kV-Chest2 kV180 MV180 kV-MVabs. dose abs. dose ratio abs. dose ratio abs. dose ratio abs. dose ratio
1 31.26mGy 9.10mGy 0 .29 0.62mGy 0 .02 40.85mGE 1 .31 20.51mGE 0 .66
2 32.00mGy 9.13mGy 0 .29 0.47mGy 0 .01 41.17mGE 1 .29 22.88mGE 0 .72
3 22.85mGy 5.22mGy 0 .23 0.27mGy 0 .01 14.06mGE 0 .62 6.60mGE 0 .29
4 23.06mGy 6.21mGy 0 .27 0.25mGy 0 .01 34.35mGE 1 .49 19.10mGE 0 .83
5 16.45mGy 4.62mGy 0 .28 0.36mGy 0 .02 33.74mGE 2 .05 15.12mGE 0 .92
6 21.54mGy 5.96mGy 0 .28 0.30mGy 0 .01 33.05mGE 1 .53 17.57mGE 0 .82
Table 3.5: Reference dose output kV-Chest1: ratio between other imaging methods and
reference (D/Dref ).
Position kV-Chest2 kV-Chest1 kV180 MV180 kV-MVabs. dose abs. dose ratio abs. dose ratio abs. dose ratio abs. dose ratio
1 9.10mGy 31.26mGy 3 .44 0.62mGy 0 .07 40.85mGE 4 .49 20.51mGE 2 .25
2 9.13mGy 32.00mGy 3 .50 0.47mGy 0 .05 41.17mGE 4 .51 22.88mGE 2 .51
3 5.22mGy 22.85mGy 4 .38 0.27mGy 0 .05 14.06mGE 2 .69 6.60mGE 1 .26
4 6.21mGy 23.06mGy 3 .71 0.25mGy 0 .04 34.35mGE 5 .53 19.10mGE 3 .08
5 4.62mGy 16.45mGy 3 .56 0.36mGy 0 .08 33.74mGE 7 .30 15.12mGE 3 .27
6 5.96mGy 21.54mGy 3 .61 0.30mGy 0 .05 33.05mGE 5 .55 17.57mGE 2 .95
Table 3.6: Reference dose output kV-Chest2: ratio between other imaging methods and
reference (D/Dref ).
measured and calculated MV dose outputs are listed in Table 3.7. In this compar-
ison RBE is not considered, i.e. the originally measured absorbed dose is shown.
The percentaged difference between measured and calculated MV dose values with
maximum difference of 2.8% underline a proper MV dose output also in low-dose
mode.
Figure 3.4: Simulation of MV-contribution
of kV-MV CBCT in Treatment Planning Sys-
tem (Oncentra Masterplan): 4MU delivered
on a 100° gantry arc.
Position
kV-MV: kV-MV:
MV part MV part percentaged
measured calculated difference
dose dose [%]
1 40.40mGy 40.26mGy 0 .35
2 44.90mGy 45.10mGy 0 .45
3 13.40mGy 13.02mGy 2 .84
4 37.30mGy 37.95mGy 1 .74
5 30.00mGy 29.82mGy 0 .60
6 34.30mGy 34.83mGy 1 .55
Table 3.7: MV dose output comparison
between measured absolute dose [Gy] and
dose calculated in a TPS (Oncentra Master-
plan) by percentaged difference calculation:
diff = (Dcalc−Dmeas)/Dmeas×100 [%].
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3.1.3 CTDI quality assurance
As a standard dose value for future QA of kV-MV CBCT, the CT dose index was
measured. For comparison, the CTDI was also measured for the other imaging
methods, the clinical presets kV-Chest1 and kV-Chest2 should result in a weighted
CTDIw with close agreement to the nominal dose value provided by the manufacturer
(see Table 2.1).
To determine the weighted CT dose index for all imaging methods, the ionization
chamber was placed at axial midpoint into the central and four periphery cavities
sequentially. Figure 3.3b shows the measurement points close-up. The CTDIw
was calculated following equation 2.17. The resulting dose values for each of the
five measurement points as well as the final weighted CTDI are listed in Table 3.8.
The MV contribution of kV-MV CBCT and MV180 dose measurement results were
converted to kV-equivalent dose by taking half of the MV dose value, similar to the
previous phantom dose study 3.1.2.
CBCT CTDIc CTDIp,0° CTDIp,90° CTDIp,180° CTDIp,270° CTDIw
kV-Chest1 9.75mGy 22.86mGy 20.64mGy 20.86mGy 28.71mGy 18.77mGy
kV-Chest2 3.42mGy 6.41mGy 6.00mGy 5.53mGy 6.74mGy 5.25mGy
kV180 0.17mGy 0.05mGy 0.58mGy 0.78mGy 0.46mGy 0.37mGy
MV180 29.40mGE 29.50mGE 24.63mGE 28.97mGE 9.16mGE 23.06mGE
kV-MV 14.70mGE 19.83mGE 16.72mGE 5.66mGE 5.74mGE 11.99mGE
Table 3.8: Determination of weighted CT Dose Index for different presets (GE: Gray-equivalent
with RBE = 2 for kV-dose distribution).
Dose comparison of kV-MV imaging vs. conventional CBCT
Table 3.9 shows the ratios between the reference CBCT kV-Chest1 and the other
imaging techniques. In Table 3.10, the ratios between imaging techniques are taken
considering kV-Chest2 the reference CBCT.
As pointed out in section 3.1.2, among each other, the clinical presets kV-Chest1
and kV-Chest2 differ in tube current per pulse duration (mAs) about a factor of
3.2, which transmits to the different dose output. This difference is also seen in
the comparison of CTDIw: The measured weighted CT dose index for kV-Chest1 is
18.77mGy, and 5.25mGy for kV-Chest2.
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With a CTDIw = 0.37mGy, the kV180 has a very small average dose output with
a minimum reduction of 99% and 86% compared to kV-Chest1 and kV-Chest2,
respectively.
For MV180, the CTDIw = 23.06mGE was 4.4 times larger than the weighted CT
dose index for kV-Chest2, but only 1.2 times larger than the CTDIw for kV-Chest1.
The kV-MV weighted CT dose index was in between both clinical presets, with
CTDIw = 11.99mGE.
Position kV-Chest1 kV-Chest2 kV180 MV180 kV-MVabs. dose abs. dose ratio abs. dose ratio abs. dose ratio abs. dose ratio
CTDIc 9.75mGy 3.42mGy 0 .35 0.17mGy 0 .02 29.40mGE 3 .02 14.70mGE 1 .51
CTDIp,0° 22.86mGy 6.41mGy 0 .28 0.05mGy 0 .00 29.50mGE 1 .29 19.83mGE 0 .87
CTDIp,90° 20.64mGy 6.00mGy 0 .29 0.58mGy 0 .03 24.63mGE 1 .19 16.72mGE 0 .81
CTDIp,180° 20.86mGy 5.53mGy 0 .27 0.78mGy 0 .04 28.97mGE 1 .39 5.66mGE 0 .27
CTDIp,270° 28.71mGy 6.74mGy 0 .23 0.46mGy 0 .02 9.16mGE 0 .32 5.74mGE 0 .20
CTDIw 18.77mGy 5.25mGy 0 .28 0.37mGy 0 .02 23.06mGE 1 .23 11.99mGE 0 .64
Table 3.9: Reference dose output kV-Chest1 for CTDI determination: ratio between other
imaging methods and reference (D/Dref ).
Position kV-Chest2 kV-Chest1 kV180 MV180 kV-MVabs. dose abs. dose ratio abs. dose ratio abs. dose ratio abs. dose ratio
CTDIc 3.42mGy 9.75mGy 2 .85 0.17mGy 0 .05 29.40mGE 8 .60 14.70mGE 4 .30
CTDIp,0° 6.41mGy 22.86mGy 3 .57 0.05mGy 0 .01 29.50mGE 4 .60 19.83mGE 3 .09
CTDIp,90° 6.00mGy 20.64mGy 3 .44 0.58mGy 0 .10 24.63mGE 4 .11 16.72mGE 2 .79
CTDIp,180° 5.53mGy 20.86mGy 3 .77 0.78mGy 0 .14 28.97mGE 5 .24 5.66mGE 1 .02
CTDIp,270° 6.74mGy 28.71mGy 4 .26 0.46mGy 0 .07 9.16mGE 1 .36 5.74mGE 0 .85
CTDIw 5.25mGy 18.77mGy 3 .58 0.37mGy 0 .07 23.06mGE 4 .39 11.99mGE 2 .28
Table 3.10: Reference dose output kV-Chest2 for CTDI determination: ratio between other
imaging methods and reference (D/Dref ).
3.2 Image Quality of kV-MV CBCT
Sufficient image quality is essential for successful image guidance in radiotherapy. In
this study, spatial resolution (section 3.2.1) and geometrical accuracy (section 3.2.2)
were evaluated for kV-MV CBCT and compared with clinical and non-clinical CBCT
alternatives.
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3.2.1 CatPhan - spatial resolution
The CatPhan phantom [2] is the most widely-used image quality assurance phantom
for CBCT. The high resolution module was scanned by kV-MV CBCT and clinical
kV-Chest1 CBCT, to evaluate clinical feasibility of kV-MV compared to a clinically
established imaging method. Figures 3.5a and 3.5b show the weighted central
phantom slices of the spatial resolution module, highlighting the highest number of
line pair discrimination for kV-Chest1 and kV-MV CBCT, respectively. For both
kV-MV and kV-Chest1, the line pairs in the third insert were still resolvable. Figures
3.5c and 3.5d display a line profile through the third line pair for kV-Chest1 and
kV-MV CBCT, respectively.
(a) CatPhan phantom scan in spa-
tial resolution module with kV-Chest1
CBCT.
(b) CatPhan phantom scan in spa-
tial resolution module with kV-MV
CBCT.
(c) Profile through third line pair
for spatial resolution analysis with
kV-Chest1 CBCT.
(d) Profile through third line pair
for spatial resolution analysis with
kV-MV CBCT.
Figure 3.5: Evaluation of spatial resolution with the CatPhan phantom for kV-Chest1 and
kV-MV CBCT.
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3.2.2 Inhomogeneous thorax phantom - tumor-shape diameter
Geometrical accuracy of kV-MV CBCT was evaluated by determining the diameters
of the four different tumor-mimicking shapes inserted in the inhomogeneous thorax
phantom. For comparison, geometrical accuracy was also determined for kV-Chest1,
kV180 and MV180. The diameters of the different tumor-inlays were measured by
manually drawing random line profiles through the tumor-mimicking shapes in each
acquired CBCT volume in Matlab and ImageJ, for both body and spikes. Each
diameter was measured three times to determine statistical deviation. Table 3.11
shows the results of diameter determination. Figures 3.6a to 3.6d show the diameter
measurement of each tumor-shaped inlay scanned with kV-MV CBCT.
body spikes
diameter diameter
[mm] [mm]
Ball nominal size 15.0
kV-MV 15.5±0.8
kV-Chest1 15.3±0.8
kV180 15.5±0.4
MV180 14.7±0.6
Cylinder nominal size 6.0 3.0
kV-MV 7.0±0.4 3.3±0.6
kV-Chest1 6.7±0.5 3.7±0.5
kV180 7.2±0.2 3.0±0.4
MV180 8.0±0.7 4.0±0.4
Star10 nominal size 10.0 5.0
kV-MV 10.2±0.6 5.3±1.0
kV-Chest1 10.7±0.9 5.3±0.5
kV180 10.2±0.6 4.8±0.2
MV180 10.2±0.6 5.8±1.0
Star15 nominal size 15.0 3.0
kV-MV 14.8±0.2 3.3±0.5
kV-Chest1 15.3±0.5 3.7±0.5
kV180 15.8±0.6 3.0±0.4
MV180 16.5±0.4 3.8±0.9
mean difference
kV-MV −0.4±0.7 −0.3±0.7
kV-Chest1 −0.5±0.6 −0.6±0.5
kV180 −0.7±0.6 0.1±0.4
MV180 −0.8±1.1 −0.9±0.8
Table 3.11: Geometrical accuracy determination of kV-MV CBCT by diameter measurement
of four different tumor-mimicking inlays with kV-MV CBCT and other clinical and non-clinical
CBCT presets.
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(a) Ball-shaped tumor-mimicking inlay.
(b) Cylinder-shaped tumor-mimicking inlay.
(c) Small star-shaped tumor-mimicking inlay.
(d) Large star-shaped tumor-mimicking inlay.
Figure 3.6: Geometrical accuracy determination of kV-MV CBCT by profile analysis through
differently-shaped tumor-mimicking inlays.
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3.3 Registration Accuracy of kV-MV CBCT
Registration accuracy of kV-MV was evaluated and compared to conventional, clini-
cally established CBCT methods. Therefore, the inhomogeneous thorax phantom
(static position) was scanned with four imaging techniques (clinical kV-Chest1, non-
clinical kV180 and MV180, as well as kV-MV), for four tumor-mimicking shapes with
10 isocenter shifts each (conducted by the same experimenter), resulting in a total
of 160 datasets. To save measurement time, kV180, MV180 and kV-MV CBCT were
acquired simultaneously. The corresponding projections were each reconstructed with
our in-house developed FDK reconstruction software [18]. To reduce the influence
of MV cross-scatter expected on the kV-detector, a filter was applied on the recon-
structed 3D volume data sets. Tests of different filters, including common median
filter, showed that a 3-dimensional Kuwahara filter [69] was the most suitable, since
it reduced noise but preserved edges.
3.3.1 Qualitative evaluation of registration accuracy
Figures 3.7a, 3.7b, 3.8a and 3.8b show the CBCT scans of each tumor shape for
different imaging techniques in a representative axial slice. In line 1, the full phantom
reconstruction is shown and in line 2, the full phantom CBCT is overlaid with the
planning CT after successful registration of shift 1 with self-developed registration
method (in-house). Line 3 and 4 display the enlarged tumor regions of line 1 and 2.
3.3.2 Quantitative evaluation of registration accuracy
The Box-and-Whisker-diagrams in Figure 3.9 give an overview of detection error
distributions, separated for different imaging techniques, registration methods and
translational directions. The results of the three registration methods followed the
same trend. Both automatic registration results validated the objective performance
of manual registration by the clinical experts.
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pCT kV-Chest1 kV180 MV180 kV-MV
Full phantom
(registered)
Full phantom 
registration
overlay
pCT
CBCT
Tumor inlay
(registered)
Tumor
registration
overlay
pCT
CBCT
(a) Ball-shaped tumor-inlay.
pCT kV-Chest1 kV180 MV180 kV-MV
Full phantom
(registered)
Full phantom 
registration
overlay
pCT
CBCT
Tumor inlay
(registered)
Tumor
registration
overlay
pCT
CBCT
(b) Cylinder-shaped tumor-inlay.
Figure 3.7: Registration results (automatic in-house method) for all imaging techniques;
kV180, MV180 and kV-MV CBCT projection data were acquired simultaneously.
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pCT kV-Chest1 kV180 MV180 kV-MV
Full phantom
(registered)
Full phantom 
registration
overlay
pCT
CBCT
Tumor inlay
(registered)
Tumor
registration
overlay
pCT
CBCT
(a) Small star-shaped tumor-inlay.
pCT kV-Chest1 kV180 MV180 kV-MV
Full phantom
(registered)
Full phantom 
registration
overlay
pCT
CBCT
Tumor inlay
(registered)
Tumor
registration
overlay
pCT
CBCT
(b) Large star-shaped tumor-inlay.
Figure 3.8: Registration results (automatic in-house method) for all imaging techniques;
kV180, MV180 and kV-MV CBCT projection data were acquired simultaneously.
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Figure 3.9: Registration of all inlays in RL, AP and CC direction for different imaging techniques and registration methods (line 1:
manual registration, line 2: automatic registration (XVI), line 3: automatic registration (in-house)).
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Table 3.12 shows the corresponding mean detection errors (± standard deviation)
as well as the maximum and minimum values. There were only minor deviations
(maximum difference 0.1mm) between mean and median of each dataset.
mean ± standard deviation detection error
CBCT kV-Chest1 kV180 MV180 kV-MV
manual registration
RL [mm] 0.1±0.3 0.4±0.3 0.2±0.4 0.5±0.3
AP [mm] −0.2±0.2 0.4±0.4 0.4±0.5 0.4±0.4
CC [mm] −0.1±0.3 −0.1±0.4 −0.1±0.5 0.0±0.4
automatic registration (XVI)
RL [mm] 0.0±0.4 0.4±0.4 0.3±0.5 0.4±0.4
AP [mm] −0.2±0.3 0.8±0.4 0.6±0.5 0.6±0.3
CC [mm] 0.1±0.4 0.1±0.5 −0.1±0.5 0.2±0.5
automatic registration (in-house)
RL [mm] 0.1±0.2 0.3±0.2 0.2±0.2 0.4±0.2
AP [mm] 0.0±0.1 0.6±0.2 0.7±0.4 0.6±0.3
CC [mm] 0.0±0.3 0.1±0.3 0.0±0.3 0.1±0.3
maximum / minimum detection error
CBCT kV-Chest1 kV180 MV180 kV-MV
manual registration
RL [mm] 0.8/−0.7 1.1/−0.3 1.2/−0.7 1.3/−0.3
AP [mm] 0.3/−0.6 1.5/−0.3 1.6/−0.6 1.4/−0.4
CC [mm] 0.9/−0.8 1.6/−1.0 1.5/−1.5 1.4/−0.9
automatic registration (XVI)
RL [mm] 0.9/−0.7 1.2/−0.5 1.5/−0.8 1.4/−0.4
AP [mm] 0.3/−1.0 1.6/ 0.2 1.8/−0.5 1.6/−0.1
CC [mm] 0.9/−0.6 1.1/−1.6 1.2/−1.3 1.3/−0.6
automatic registration (in-house)
RL [mm] 0.3/−0.3 0.8/−0.2 0.6/−0.2 0.9/ 0.0
AP [mm] 0.2/−0.2 1.1/ 0.2 1.4/−0.1 1.2/ 0.0
CC [mm] 0.6/−0.6 1.1/−0.4 1.0/−0.6 1.4/−0.4
Table 3.12: Detection errors for different imaging techniques and registration methods,
representing the average of four tumor-inlays and 10 isocenter shifts as well as corresponding
maximum and minimum detection errors.
Averaged over all registration methods, kV-MV CBCT detection errors were (0.4±
0.3)mm in RL, (0.5±0.3)mm in AP and (0.1±0.4)mm in CC direction. Maximum
detection errors were 1.4mm (RL and CC) and 1.6mm (AP), whereas maximum RL
and AP offset were detected with automatic registration method (XVI), maximum
CC error with automatic registration (in-house). In comparison, clinical kV-Chest1
CBCT detection errors were (0.1± 0.3)mm in RL, (−0.1± 0.2)mm in AP and
(0.0±0.1)mm in CC direction, with maximum detection errors of 0.9mm in RL and
CC direction, and 0.3mm in AP.
Overall maximum detection errors were distinguished in automatic registration
(XVI) method of MV180 CBCT for RL (1.5mm) and AP (1.8mm) direction. In
CC direction, MV180 CBCT closely followed the largest offset of kV180 CBCT with
1.2mm.
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3.3.3 Significance-Test between different imaging techniques
and registration methods
With the Kolmogorov-Smirnov test [75] provided in Matlab, all measurement datasets
were tested negatively for normal distribution. Thus, the choice of paired difference
test from Wilcoxon [100] was justified.
As shown in Table 3.13, the paired difference test between kV-MV and kV-Chest1
CBCT confirmed a significant offset in RL and AP direction (p < 0.01), since kV-MV
had a detection error bias of up to ±0.5mm. In CC direction, differences were not
significant (p= 0.33−0.81). Comparison between kV-MV and kV180 as well as MV180
showed mostly no significant differences, since all three imaging techniques suffered
from image degradation for similar reasons.
kV-Chest1 vs. kV-MV kV180 vs. kV-MV MV180 vs. kV-MV
manual registration
RL < 0.001 < 0.001 < 0.001
AP < 0.001 0.783 0.451
CC 0.809 0.551 0.277
automatic registration (XVI)
RL 0.004 0.806 0.240
AP < 0.001 0.006 0.868
CC 0.805 0.554 0.004
automatic registration (in-house)
RL < 0.001 < 0.001 < 0.001
AP < 0.001 0.767 0.183
CC 0.333 0.485 0.002
Table 3.13: P-values determined with paired difference test between kV-MV and other imaging
techniques
The second paired difference test (Table 3.14) showed significant advantage of manual
vs. both automatic registration methods (p < 0.05) for the major imaging techniques
kV-MV and kV-Chest1 CBCT. This is because manual registration detection er-
ror results were closest to zero, followed by in-house registration. For automatic
registration (XVI), detection errors were spread out widest.
direction CBCT manual vs. automatic manual vs. automatic automatic registration:(XVI) registration (in-house) registration XVI vs. in-house
RL kV−Chest1 0.023 < 0.001 0.840kV−MV 0.036 0.001 0.872
AP kV−Chest1 0.198 < 0.001 < 0.001kV−MV 0.001 < 0.001 0.747
CC kV−Chest1 0.003 0.076 0.014kV−MV 0.005 0.003 0.216
Table 3.14: P-values determined with paired difference test between all three registration
methods for clincal kV-Chest1 and novel kV-MV CBCT
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In-house developed ultrafast combined kV-MV CBCT was recently successfully
established and the workflow is fully automated [15, 17]. Enabling image times of
only 15s is a very promising alternative for DIBH- patients suffering from lung
cancer [23].
Clinical CBCT acquisition takes at least 30s, since 180° gantry rotation is a minimum
requirement for sufficient image registration, and the gantry speed is limited to 1rpm
by law. In 2014, Zhong et al. [107] implemented and evaluated single-breath-hold
CBCT and evaluated it based on patient studies. In their study, however, the
single-breath-hold time was limited to minimum 40s. Following McNair et al. [77],
imaging times of 30s or more limit the applicability of imaging within single breath-
hold to a small percentage of patients. Their recommended achievable breath-hold
time for patients with non-small cell lung cancer was 15s. Thus, for most patients,
imaging with the fastest achievable imaging technique requires minimum one imaging
interruption for free breathing. Total imaging time is increased to minimum 40s.
A possible improvement from 30s to 15s makes thus a significant difference for a
fair percentage of the lung cancer population. With a fast imaging technique of
data acquisition within single-breath-hold, not only the patient comfort could be
improved and the treatment delivery chain accelerated, but also potential image
quality degradation and repositioning inaccuracies due to residual or intrafractional
breathing motion could be prevented. It is therefore aspired to implement combined
kV-MV CBCT into clinical routine.
For legal approval however, clinical feasibility of kV-MV CBCT has to be investigated.
The aim of this thesis was to develop concepts to evaluate the properties of kV-MV
CBCT, to accomplish the phantom measurements and to evaluate and compare
the results with conventional, clinical and non-clinical imaging techniques. This
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thesis focused on the following clinically required qualities of image guidance systems:
(1) dosimetry, (2) image quality and (3) registration accuracy. In the following
subsections, the accomplished results are discussed for each kV-MV CBCT property.
4.1 Dosimetric properties of kV-MV CBCT
The major concern of the novel approach of kV-MV CBCT is the dose exposure
to the patient. Most commonly, image guidance is performed with kV-CBCT. The
MV-contribution of kV-MV CBCT could thus be a critical dosimetric issue towards
clinical implementation. Dosimetric properties of kV-MV CBCT were evaluated and
compared with other clinical (kV-Chest1, kV-Chest2) and non-clinical (kV180, MV180)
imaging techniques.
4.1.1 Optimal dose calibration
For proper and reliable dosimetry, the ionization chambers had to be calibrated. Two
point-dose ionization chambers of the same type were applied, one was calibrated
on air kerma (kV-range), the other one on absorbed dose-to-water (MV-range), to
perform appropriate dosimetry for kV and MV contributions in the measurement
studies. Beam qualities of kV and MV energies were determined. Half value layer
measurements as specification of kV beam quality were performed for all kVp and
mAs combinations applied in this study. Extensive research was performed to find an
appropriate fit for measurement values, considering the beam hardening effect. The
method of Bjärngard/Shackford [14] resulted in a proper fit to our HVL measurement
data and thus their mathematical approach was used to calculate the HVL for our
imaging techniques with kV contribution. The resulting HVLs were in accordance
with literature. MV beam quality index was determined by measuring a percentage
depth dose curve with a water tank. In the treatment planning system of our clinic,
a quality index of Q= 0.68 is used in case of the 6MV linac output. LINAC1 was
calibrated accordingly. Our measurement of Q showed a deviation of less than 1%.
To compare both kV and MV dose output with each other, MV dose was converted to
kV-equivalent dose. Following recommendations in literature, as discussed in section
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2.3.3, a conservative relative biological effective conversion ratio of 2 vs. 1 was chosen
for kV vs. MV dose, respectively. Thus, the dose output of the MV contribution of
kV-MV CBCT and MV180 CBCT was halved. To distinguish between measured MV
dose and kV-equivalent MV dose, the unit of kV-equivalent MV dose was adapted to
Gray-equivalent [GE].
4.1.2 Dose exposure of kV-MV CBCT
The dose exposure of kV-MV CBCT was evaluated with regard to two different
aspects. First, dose measurements were performed in an inhomogeneous thorax
phantom (CIRS) to simulate a patient case. Dose output was measured in six
representative body sites, such as the target location in the lower left lung, both
lungs, spinal cord, body center and upper periphery. Second, a CT Dose Index
(CTDI) was determined as standard dose value for future quality assurance.
In the inhomogeneous thorax phantom, kV-MV CBCT dose as the sum of kV
contribution and kV-equivalent MV contribution, varied from 6.60−22.88mGE. The
difference in dose values is due to the asymmetric dose distribution arising from the
limited gantry angle rotation of combined 90° kV and 90° MV beam. The maximum
dose was measured at the left lung, which was at the location where the kV and MV
contributions overlapped (90° gantry angle position). Due to the asymmetric dose
distribution, healthy tissue could be spared; the minimum dose was measured in the
contralateral lung.
The determined weighted CT dose index was 11.99mGE for kV-MV CBCT. In
this homogeneous phantom, the asymmetric dose property of kV-MV is clearly
demonstrated: highest dose output is detected at 0− 90°, this is where the MV-
contribution was highest. The lowest dose output was measured in the contralateral
cavities, at 180− 270° gantry angles. The central cavity showed a rather large
measure. This is because MV beams travel farther than kV beams.
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4.1.3 Comparison of all applied imaging techniques, including
kV-MV
For both phantom studies, the novel kV-MV CBCT dose output was compared with
two clinically established CBCTs, kV-Chest1 and kV-Chest2. To allow comparison
to fastest-achievable conventional monoenergetic CBCT, the dose output of kV180
and MV180 CBCT was also measured.
Averaged over all measurement points, the ratio between the widely-used kV-Chest1
and the latest available kV-Chest2 CBCT was 3.6, i.e. both thorax phantom and
CTDI measurements are in agreement with the nominal dose ratio of 3.2 provided by
the manufacturer. The measured CTDIw of the kV-Chest1 preset was 18.77mGy,
thus approximately 15% higher than the nominal dose of 16mGy. Following the
manufacturer, a dose deviation of ±35% is still within the limits [37]. The deviation
to the nominal dose value of kV-Chest1 could be related to the advanced age of the
x-ray tube of LINAC1 (installation: 2010).
The dose output of kV180 was significantly smaller (92− 98%) than both clinical
presets. This remarkable dose reduction is due to the bisection of angle rotation,
the reduced kVp (100kVp vs. 120kVp of clinical presets) as well as the immense
reduction of mAs (see details in Table 2.1).
A major concern in dosimetry is MV CBCT. With the development of combined
kV-MV CBCT, also low-dose MV180 CBCT could have potential for future clinical
application due to metal artifact reduction, and was thus included in this comparison
study. In our dosimetry studies, maximum kV-equivalent MV dose output was
41.17mGE. This was maximum twice as large as the widely-used clinical kV-Chest1
preset. Remarkable, however, was the dose reduction in the contralateral lung
compared to kV-Chest1. This could be explained by the asymmetric arrangement of
the phantom relative to the isocenter, i.e. the contralateral lung was only irradiated
indirectly by the MV beam. Especially for MV180 CBCT an enlarged central body
dose was observed compared to kV-Chest1 and kV-Chest2.
The kV-MV CBCT dose output and clinical kV-Chest1 were in a comparable range
(66% to 92%) in most positions. Special attention has to be given to the healthy
right lung, where the dose was 2/3 lower than the clinical preset. Thus, the healthy
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tissue could be even spared, although this was not expected in advance. Compared
to latest available kV-Chest2, the kV-MV CBCT dose is maximum 3.3 times higher.
This dose value of 15.12mGE occured at the body center and is close to what was
measured for the kV-Chest1 preset (16.45mGy). The minimum kV-MV dose was
measured in the contralateral lung where the dose was almost the same as for the
kV-Chest2 preset. In case of the kV-Chest1 preset, the dose was even more than 3
times higher compared to the dose of the kV-MV approach.
4.1.4 Imaging dose in the clinical context
In the last decade, many studies on kV dosimetry with CBCT in particular were
published [12, 80]. Most of them performed dose measurements with the clinical
presets provided by the manufacturers. They either measured the CTDI [4,94], or
tried to estimate imaging dose to the patient either by phantom measurements [32,59]
or Monte Carlo simulations [33,63].
The clinical CBCT presets kV-Chest1 and kV-Chest2 are in close agreement with
literature and so is consequently kV-MV CBCT.
Another yet theoretical approach to combine kV and MV imaging was performed by
Liu et al in 2015 [71]. Their approach is promising regarding MV to kV grey value
conversion for acceptable image quality. Their high imaging doses of 50−200cGy,
however, make a clinical implementation impossible at this stage of research.
In rare cases, MV CBCT is applied in clinical routine. Pouliot et al. [85] published a
dosimetry study performed on a Siemens Primus linac with integrated MV CBCT.
They reduced the dose pulse rate to 0.01MU/°, however their dose measure over a
180° gantry arc was still 50−150mGy and thus had to be considered in the total
dose to the patient by adding the dose to the treatment plan.
In 2015, Liu et al. [71] published a paper about MV-CT installed on a Hi-Art
Tomotherapy unit. After detuning the incident electron beam from 6MV to 3.5MV
in imaging mode, the weighted CT dose index was in the range of 20mGy.
The low-dose MV CBCT approach provided by our development of combined kV-MV
CBCT could be an alternative in case of metal body components close to the target
location. MV dose could reduce occuring metal artifacts [87].
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Considering the build-up effect in case of high energies which leads to reduced dose
on the surface for MV energy, combined kV-MV imaging could also reduce dose
exposure to sensitive patient skin.
The last but yet most important aspect of the dosimetric properties of kV-MV
CBCT is, that determined imaging doses of approximately 22mGE remain negli-
gibly small compared to the prescribed dose of the treatment plan. Especially for
hypofractionated SABR, fractional doses of 5−20Gy are common in clinical routine.
4.2 Image Quality of kV-MV CBCT
The essential prerequisite for successful image registration for patient positioning prior
to radiation treatment is sufficient image quality. To investigate clinical feasibility of
novel kV-MV CBCT, the spatial resolution and geometrical accuracy was evaluated
and compared to the clinically established kV-Chest1 CBCT.
4.2.1 Spatial resolution
The spatial resolution of novel kV-MV CBCT is in agreement with the clinically
established kV-Chest1 CBCT. By visual judgment, both imaging methods showed
clear discrimination up to the third line pair. Since the gap between the single rods
was 1.67mm, the peak to peak spatial resolution of both kV-MV and kV-Chest1
resulted in 3.34mm.
Other studies published on spatial resolution of CBCT presets [105] are not compara-
ble to our investigation, since they analyze the spatial resolution of presets especially
generated for quality assurance, and not clinical presets. Thus, our novel kV-MV
CBCT approach could only be compared to the direct alternative clinical kV-Chest1
preset.
4.2.2 Geometrical accuracy
Geometrical accuracy of kV-MV CBCT was determined and compared with clinical
and non-clinical CBCT methods by measuring the diameter of four different tumor-
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mimicking shapes in the inhomogeneous thorax phantom. Manual evaluation by
linear profiles resulted in a mean deviation of (−0.4± 0.7)mm for the body and
(−0.3±0.7)mm for the spikes between nominal size provided by the manufacturer
and kV-MV CBCT, whereas the mean deviation for kV-Chest1 was (−0.5±0.6)mm
(body) and (−0.6± 0.5)mm (spikes). The maximum deviation for the body was
1.5mm and 2.0mm for kV-MV CBCT and kV-Chest1, respectively.
The non-clinical CBCT presets, kV180 and MV180, had a larger mean deviation of
(−0.7±0.6)mm (body), (0.1±0.4)mm (spikes) and (−0.8±1.1)mm (body), (−0.9±
0.8)mm (spikes), respectively. This is due to the degraded image quality, further
discussed in section 4.3.3 in the registration accuracy study. For kV180, a projection-
overlap artifact of reduced edge sharpness was detected in anterior-posterior direction
due to the additional cone-angle. MV180 suffered from aliasing artifacts due to
strong undersampling, as well as poor MV soft-tissue contrast [87]. MV-cross-scatter
in kV-MV CBCT however did not lead to image quality degradation in terms of
inaccurate geometry, as was also evaluated in 2007 by Nakagawa et al. [81].
Overall, kV-MV CBCT is conform with the image quality of the clinical kV-Chest1 in
high contrast areas as it is the case for a lung tumor. It can thus be concluded that
kV-MV CBCT has sufficient image quality to be implemented into clinical routine.
4.3 Registration Accuracy of kV-MV CBCT
The registration accuracy of our in-house developed combined kV-MV CBCT imaging
technique, allowing image acquisition within one breath-hold, was determined. To
guarantee accurate patient imaging and repositioning under clinical conditions,
kV-MV CBCT was compared to a conventional, clinically established technique
(kV-Chest1) as well as non-clinical fastest-achievable monoenergetic CBCTs (kV180
and low-dose MV180) in a pre-clinical study.
In this study, static phantom measurements were performed; in-between breathing
phases and potential repositioning inaccuracies were not considered.
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4.3.1 Optimal registration method
An advantage of manual registration over automatic approaches is to overcome
possible mismatching or trapping in local minima during the automatic matching
process. To also provide objective validation of manual matches by three clinical
experts, two automatic registration methods were additionally applied: (1) with XVI
CBCT software and (2) with self-developed rigid registration framework in Matlab
(called ”in-house” in this study).
In contrast to the automatic registration (XVI) method, the self-developed automatic
registration method provided objective comparison between the different imaging
techniques. While XVI requires manual setting of an alignment box for each regis-
tration, the self-developed framework enabled automatic registration of all datasets
without manual interaction. Furthermore, the self-developed framework assured
the same alignment box per isocenter shift for all imaging methods, which is a
prerequisite for proper objective comparison.
All three methods resulted in mean displacement errors between (0.0− 0.8)mm,
which is the currently achievable precision with volume imaging in clinical routine.
Both automatic registration methods showed significant differences when compared
to manual registration. The largest registration errors and biggest standard devia-
tions were observed with automatic registration (XVI) across all imaging paradigms,
including the clinical kV-setup. This can be attributed to high sensitivity of image-
based registration to image artifacts, and confirms manufacturer recommendations
of interactive (manual) verification of automatic registration results. The absolute
maximum error in all matching attempts was 1.6mm for manual matching, thus
fulfilling the clinical requirements without exception.
4.3.2 Estimation of measurement setup error
Similar registration accuracy studies to assess different clinically used imaging
modalities were performed by Yan et al. [103], Ballhausen et al. [10] and Meyer et
al. [78]. Each study used a different approach to handle setup error as well as the
clinical couch uncertainty of ±0.5mm:
• Yan et al. evaluated the mechanical accuracy of the Varian OBI CBCT system.
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They aligned a rigid pelvis anthropomorphic phantom on the couch with the
help of fiducial markers and room lasers. The initial scan in isocenter was
registered automatically and the random setup error was recorded. Pseudo-
random known isocenter shifts were applied and CBCT scans were repeated.
The detected isocenter offsets were corrected for setup error by subtraction
of the previously determined random setup error, and the resulting corrected
detector offsets were compared with actually applied couch offset. Mostly,
registration was performed with automatic registration code provided by the
manufacturer. In cases where visual examination was not sufficient, manual
registration was performed. Outliers were excluded from the study since there
was no clear trend observable. However, they did not handle the fact of limited
mechanical resolution of 1mm for the treatment couch. Thus, the actual
manually simulated shift had an inaccuracy of ±0.5mm. Results (mean ±
standard deviation), including couch uncertainty, were (0.3±0.6)mm in RL,
(0.3± 0.6)mm in CC and (0.4± 0.6)mm in AP direction. Thus, they could
conclude to identify the target within 1mm [103].
• Ballhausen et al. performed a comparison study between the different position-
ing modalities of skin markers, ultrasound system and kV-CBCT. In their study,
controlled phantom displacement was achieved by aligning the phantom with
laser markers and mm−scales attached to the phantom. Different isocenter
shifts were performed, image volumes were acquired and displacement errors
were calculated with automatic image registration. To account for setup errors,
a consensus value was calculated from all collected displacement errors for each
modality, and the final displacement errors were compared relatively to this
consensus value. Overall, the displacement offsets were below 1mm [10].
• Meyer et al. presented a registration accuracy study with the Hexapod robotic
treatment table (Medical Intelligence, Medizintechnik GmbH, Schwabmünchen,
Germany). The movement of the Hexapod couch was computer-controlled
(iGuide), accurate positioning was ensured by means of an optical tracking
system (Polaris, NDI, Waterloo, Ontario, Canada), consisting of optical sensors
on a rigidly attached couch bridge and an infrared tracking camera. The
accuracy of the optical tracking system was 0.35mm. In their study, only
one CBCT scan was performed in isocenter position; the isocenter shifts were
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conducted in the treatment planning software on the planning CT dataset. This
procedure ensured the isocenter shifts to be independent of the measurement
system and any setup errors. All displacement errors were compared relative
to the first registration in isocenter position. Registration was performed with
the automatic registration algorithm provided by the manufacturer. Results of
mean offset varied between (0.2−0.3)mm in all three translational directions,
maximum absolute error was 0.6mm [78].
Similar to the study in this thesis, they all concluded registration accuracy to be
below 1mm under clinical conditions with current imaging tools. Here, the couch
isocenter offsets were realized using precise optical tracking (step width: 0.1mm).
The initial isocenter position was ensured with an accuracy of 0.05mm. Each couch
shift relative to this zero position could be defined as reference for latter detection
error calculation.
4.3.3 Registration accuracy for combined kV-MV CBCT
The mean displacement errors of kV-MV CBCT for manual registration were (0.5±
0.3)mm in RL, (0.4± 0.4)mm in AP and (0.0± 0.4)mm in CC direction; outliers
were included. The results differed only slightly among the imaging techniques. As
expected, the kV-Chest1 preset had the smallest mean error and standard deviation.
The kV180, MV180 and kV-MV CBCT registration results were in the same range
(mean value between 0.0−0.8mm). The largest detection errors occured for MV180
CBCT, as expected due to poorest image quality compared to the others. For all
imaging techniques, the mechanical registration offsets were, nevertheless - apart from
very few outliers - below 1mm, being within the manufacturer’s specified accuracy
range for standard clinical CBCT. Figures 3.7a, 3.7b, 3.8a and 3.8b demonstrate
that image quality is sufficient even for undersampled image information in the MV
contribution of kV-MV CBCT and in MV180 CBCT; the tumor shape is clearly
visible for all imaging techniques, the registration lies within 1/2pixel accuracy.
More specific evaluation is discussed in the following:
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Interpretation of registration detection errors
As expected, clinical kV-Chest1 CBCT results showed smallest detection errors with
lowest fluctuations in all directions. The image quality was highest compared with
other imaging techniques in this study due to the larger number of projections
collected over a full 360° gantry arc.
For kV180, MV180 and kV-MV CBCT, the mean detection errors in CC direction
were also close to zero (on average (0.0±0.4)mm, maximum detection error 1.6mm).
However, for RL and AP direction, the mean was non-zero. This small but noticable
bias of up to +0.5mm in transverse slice could be explained by degraded image
quality due to the following reasons:
• MV-cross-scatter was encountered on the kV-detector in all three imaging
techniques due to simultaneous image acquisition.
• kV180: Overlapping projections due to the additional cone-angle lead to a slight
stripe artifact in AP-direction and reduced edge sharpness of the tumor-shape
in transverse slices (Figures 3.7a, 3.7b, 3.8a and 3.8b).
• MV180: Aliasing artifacts occured due to strong undersampling, as well as poor
MV soft-tissue contrast [87].
• kV-MV: The MV contribution was undersampled and had worse soft-tissue
CNR than kV contribution. However, the MV contribution still had strong
impact on edge contours of the high contrast areas [79, 85], and thus the lung
tumor shape was clearly apparent in kV-MV CBCT (Figures 3.7a, 3.7b, 3.8a
and 3.8b).
Evaluation of detection error outliers
Outliers in CC direction for manual and automatic (in-house) registration in simul-
taneously acquired kV180, MV180 and kV-MV CBCT (Figure 3.9) occured in case of
the second isocenter shift applied on the small star-shaped tumor inlay. Since the
following consecutive shifts showed smaller detection errors, a positioning error of
the experimenter is unlikely. The detection error rather attributed to the interplay of
degraded image quality, as well as error-prone software interpolation for challenging
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star-shaped tumor-inlay of diameter 10mm; in planning CT the slice-to-slice variation
is large due to a slice thickness of 1mm. As a matter of fact, the marginal volume
sizes of all four tumor-mimicking shapes induce most challenging test paradigms for
registration accuracy. Outliers in kV-Chest1 for manual registration in CC direction
attribute to erroneous matching by the same physician. Even though these detection
errors only range from 0.6−0.9mm, they are considered as outliers, because other de-
tection errors in this larger number of measurement values are close to zero. Settings
for Box-and-Whisker-diagrams were the same, disregarding the different number
of measurement values for manual or automatic registration. In total, outliers of
manual registration amount to 4% of all 480 measurement values, whereas 2.5% of
all outliers were > 1mm.
Overall systematic and stochastic error evaluation
Overall, the systematic error was reduced to < 0.05mm by mechanical stability
and geometrical accuracy of iGuide, which was stable over the whole measurement
time. The stochastic mean error was between 0−0.5mm also due to limited dataset
resolution. Pixel size and slice thickness differed for all 3D volume datasets. For the
four planning CTs, the slice thickness was 1mm and the pixel size varied between
0.8516 and 0.8809mm, depending on field of view. For kV-Chest1 CBCT, the pixel
size and slice thickness were 1mm; and 0.5mm for kV180, MV180 and kV-MV CBCT.
Thus, the registration offset of only one pixel could potentially result in an offset
of 0.5mm. Since the currently achievable precision in clinical routine is ±1mm,
systematic and stochastic errors in this study are within the given limit.
4.3.4 Additional benefits of image acquisition in one breath-hold
To image lung tumors in breath-hold, the factor of tumor repositioning between
two breath-hold phases had to be considered for overall imaging accuracy. Koshani
et al [67] evaluated the short- and long-term reproducibility of intrathoracic tumor
position using ABC within a patient study. Results of intra-fractional reproducibility
as a measure for the movement between two breath-hold phases was (0.2±0.7)mm in
RL, (0.0±1.5)mm in AP and (0.3±1.4)mm in CC direction, maximum displacements
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were 1.7mm, 3.1mm and 4.2mm, respectively.
Avoiding these additional defective fluctuations between breath-hold phases in com-
bination with shorter total imaging time and increased patient compliance further
increases overall treatment precision.
4.3.5 Conclusion for kV-MV registration accuracy
This study showed that there is no degradation of registration accuracy with kV-MV
CBCT compared to the other techniques including clinical standard kV-CBCT.
All other techniques, however, require at least a scan angle of 180°, corresponding to
at least 30s scan time. To prevent respiratory motion, the data acquisition process
needs to be interrupted. To allow the patient to breathe, effective imaging times of
40−200s have to be accepted. Furthermore, this may lead to reduced image quality
due to intra-fractional repositioning errors.
4.4 Final Conclusions
Combined ultrafast kV-MV cone-beam computed tomography (CBCT) is a promising
approach to accelerate imaging for patients with lung tumors treated with deep
inspiration breath-hold (DIBH). During a single breath-hold phase of 15s, a combined
90°+90° kV-MV CBCT can be acquired, reducing motion artifacts to a minimum and
increasing patient comfort in comparison to repeated breath-hold imaging techniques.
Combined kV-MV CBCT development was recently finalized within our research
group.
To judge clinical feasibility, kV-MV CBCT has to be compared to clinically established
repeated breath-hold based imaging methods serving the same purpose in clinical
routine. Since imaging times of these clinical presets are 3−4min including breath-
hold interruptions, two additional monoenergetic (kV and MV) fastest achievable
imaging methods (imaging times of 30−40s) were defined and compared with.
The aim of this thesis was to develop the concepts of testing the clinically-relevant
properties of kV-MV CBCT: (I) dose exposure, (II) image quality and (III) registration
accuracy. These tests were accomplished for kV-MV CBCT and other conventional
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CBCT methods, followed by detailed evaluation and comparison. In particular, the
three characteristic studies were performed as follows:
• (I) Dosimetric properties: For a reliable measurement of the absorbed
dose in the imaging process, accurate dose calibration was performed for kV
and MV energy. Extensive research was done to determine beam quality for
both energy ranges. For direct comparison of MV to kV dose output, the
MV dose was converted into kV-equivalent dose by considering the changes in
relative biological effectiveness between kV and MV energies. Two dosimetry
studies were performed: (1) patient simulation based on an inhomogeneous
thorax phantom with measurements in various representative locations, and (2)
determination of CT dose index (CTDI) for future quality assurance purposes.
Results show comparable results of 20.5mGE (Gray-equivalent) with the widely-
used clinical imaging technique in the target region, whereas kV-MV spared
healthy tissue and reduced dose to 6.6mGE (30%) due to asymmetric dose
distribution. Compared to the latest available clinical preset (9.1mGy target
dose), the kV-MV approach was maximum 3 times larger, however still minimum
8 times faster which justifies application of kV-MV for hypofractionated DIBH.
CTDI result for kV-MV lied in between both clinical presets with a weighted
CTDI of 12mGE.
• (II) Image Quality: Comparison tests on image resolution and geometrical
accuracy were performed. Image resolution was determined with a CatPhan
phantom commonly used for quality assurance of CBCT. The geometrical
accuracy was investigated on differently shaped tumor-mimicking inlays in an
inhomogeneous thorax phantom. Compared with the other clinical and non-
clinical imaging methods, image quality and image constancy were sufficient
particularly for high contrast objects such as lung tumors.
• (III) Registration accuracy: Precise patient positioning before treatment is
the quintessence for implementation of a novel imaging technique such as kV-MV
CBCT. Therefore, a detailed phantom registration study was performed with
different tumor-mimicking shapes in an inhomogeneous thorax phantom. 10
random pre-selected isocenter shifts were applied and served as gold standard for
latter detection error evaluation. High precision phantom positioning (0.05mm
accuracy) could be achieved by optical tracking, practically eliminating residual
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setup error. Registration was performed with three methods: (1) manual, (2)
automatic software provided by manufacturer, and (3) self-developed automatic
registration framework. Self-developed automatic registration enabled proper,
objective evaluation by automatic determination of identical region of interest
around the tumor-shapes for all imaging techniques. Mean displacement
errors were (0.5± 0.3)mm in right-left, (0.4± 0.4)mm in anterior-posterior
and (0.0± 0.4)mm in craniocaudal direction for kV-MV CBCT and manual
registration. Manual registration emerged to be the most accurate method
with smallest detection error variability and maximum errors of no more than
1.4mm for kV-MV. Both automatic registration methods validated objectively
the performance of the clinical experts.
In summary, the comparison studies conceptualized and accomplished in this thesis
demonstrated that kV-MV CBCT is feasible for imminent clinical implementation:
dosimetric properties were in agreement with common clinically established imaging
techniques, whereas exposure to healthy tissue was reduced. Image quality and geo-
metrical accuracy was sufficient particularly for high contrast areas, and registration
accuracy was maintained below 1mm. All requirements for successful implementation
of single-breath-hold kV-MV CBCT into clinical routine are thus fulfilled.
The combination of single-breath-hold ultrafast kV-MV CBCT imaging (∼ 15s),
target re-positioning (∼ 2min) and fast deep-inspiration breath-hold flattening-filter-
free SABR (∼ 2−4min) would reduce the total treatment time to 10−15min. With
this combination of fast imaging and fast treatment, patient on-couch time would be
tremendously reduced, improving the patient comfort and compliance. Treatment
precision would be enhanced by reducing the number of necessary breath-hold phases
to a minimum.
With the constant optimization regarding technical aspects of detector panel readout
and scatter correction algorithms, improvements in image quality and thus possible
reduction of MV dose output could be feasible in the near future. Furthermore,
enhanced image quality could allow application to other tumor sites such as liver
tumors.
81
4 Discussion and Conclusion
Combined kV-MV CBCT is a promising new imaging technique which could soon
be applied to the first lung cancer patients, with high potential in bringing the
whole treatment delivery of image guided DIBH FFF-SABR to the currently fastest
achievable level.
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A Appendix
A.1 Measurements of Half-Value-Layers for
kV-energy beam quality determination
Al [mm] kV-Chest1 kV-Chest2
kV-contribution
of kV-MV
total dose [mGy] normalized total dose [mGy] normalized total dose [mGy] normalized
0 1.764 6.508 1.171
0 1.766 6.499 1.173
0 1.774 6.562 1.181
0 1.782 6.552 1.190
mean 1.772 1.000 6.530 1.000 1.1788 1.000
1.06 1.586 0.895 5.780 0.885 1.013 0.859
2.06 1.440 0.813 5.189 0.795 0.885 0.751
3.11 1.306 0.737 4.666 0.715 0.772 0.655
4.11 1.213 0.685 4.198 0.643 0.686 0.582
4.62 0.663 0.563
5.14 1.093 0.617 3.839 0.588 0.620 0.526
5.45 0.605 0.513
5.60 0.595 0.505
5.64 0.589 0.500
5.65 0.589 0.499
5.70 0.586 0.497
5.80 0.581 0.493
6.00 0.568 0.482
6.20 1.003 0.566 3.511 0.538 0.557 0.473
6.60 0.965 0.545 3.351 0.513 0.521 0.442
7.00 3.299 0.505 0.509 0.431
7.10 3.285 0.503
7.15 3.267 0.500
7.20 0.916 0.517 3.226 0.494 0.491 0.416
7.40 0.905 0.511 3.160 0.484 0.482 0.409
7.60 0.888 0.501 3.119 0.478 0.473 0.402
7.65 0.885 0.499
7.66 0.882 0.498
7.70 0.880 0.497
7.80 0.872 0.492
8.00 0.858 0.484 2.990 0.458 0.456 0.387
8.26 0.842 0.476
9.25 0.783 0.442 2.735 0.419 0.408 0.346
10.31 0.716 0.404 2.517 0.385 0.365 0.310
Table A.1: Measurement data of Half-Value-Layer for kV-Chest1, kV-Chest2 and kV contri-
bution of kV-MV CBCT.
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A.2 Matlab Code: (III) Objective automatic
registration with self-developed software
(in-house)
1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
2 %% Automatic Registration (in-house) %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
3 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
4 %% AUTHOR: Anna Arns (anna.arns@umm.de) - July 2015
5 %%
6 % input data:
7 % Vol_pCT = Vol_fixed ; PixelSize: ps_fixed ; SliceThickness: st_fixed ;
8 % ISO_fixed
9 % Vol_CBCT = Vol_moving ; PixelSize: ps_CBCT ; SliceThickness: st_CBCT
10 %
11
12 %% DATA to be evaluated
13 Phantoms = {'Ball' , 'Cylinder' , 'Star10' , 'Star15' };
14 Method = {'kV-MV' , 'kV-180' , 'MV-180', 'kV_Chest'};
15 % for shifts 1-10
16 % alignment box: 18 pixel from center in all 3 directions
17 ab = 18;
18 %...
19 %.... loop for data (not included in this code)
20 %...
21
22 %% load fixed data
23 [Vol_fixed, ps_fixed, st_fixed, ISO_fixed] = ...
24 MyF_load_Vol_fixed(datapath_fixed);
25
26 %% load moving data
27 switch Method
28 case 'kV-MV'
29 [Vol_moving, ps_moving, st_moving] = ...
30 MyF_load_kVMV(datapath_moving);
31 case 'kV-180'
32 [Vol_moving, ps_moving, st_moving] = ...
33 MyF_load_kV180(datapath_moving);
34 case 'MV-180'
35 [Vol_moving, ps_moving, st_moving] = ...
36 MyF_load_MV180(datapath_moving);
37 case 'kV-Chest'
38 [Vol_moving, ps_moving, st_moving] = ...
39 MyF_load_kV_Chest(datapath_moving);
40 end
41
42 %% 1. generate alignment box
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43 % fixed volume: (ISO_fixed is given in world coordinates - intrinsic
44 % coordinates are required)
45 col_fixed = [(round(ISO_fixed(1)/ps_fixed)-ab+1):...
46 (round(ISO_fixed(1)/ps_fixed)+ab)];
47 row_fixed = [(round(ISO_fixed(2)/ps_fixed)-ab+1):...
48 (round(ISO_fixed(2)/ps_fixed)+ab)];
49 slice_fixed = [(round(ISO_fixed(3)/st_fixed)-ab+1):...
50 (round(ISO_fixed(3)/st_fixed)+ab)];
51 Vol_fixed_ab = Vol_fixed(row_fixed, col_fixed, slice_fixed);
52 trafo_fixed_ab = [(col_fixed(1)-1)*ps_fixed, ...
53 (row_fixed(1)-1)*ps_fixed, ...
54 (slice_fixed(1)-1)*st_fixed];
55
56 % moving volume: (center values of rough tumor-shape position assumed by
57 % a priori isocenter shift information (for in total 10 shifts))
58 col_moving = [(cen_col_moving-ab+1):(cen_col_moving+ab)];
59 row_moving = [(cen_row_moving-ab+1):(cen_row_moving+ab)];
60 slice_moving = [(cen_slice_moving-ab+1):(cen_slice_moving+ab)];
61 Vol_moving_ab = Vol_moving(row_moving, col_moving, slice_moving);
62 trafo_moving_ab = [(col_moving(1)-1)*ps_moving,...
63 (row_moving(1)-1)*ps_moving, ...
64 (slice_moving(1)-1)*st_moving];
65
66 disp('Alignment box set for fixed and moving volume.');
67
68 %% convert from intrinsic to world coordinate system
69 % full volumes
70 R_fixed = imref3d([length(Vol_fixed(:,1,1)), length(Vol_fixed(1,:,1)), ...
71 length(Vol_fixed(1,1,:))], ps_fixed, ps_fixed, st_fixed);
72 R_moving = imref3d([length(Vol_moving(:,1,1)), length(Vol_moving(1,:,1)), ...
73 length(Vol_moving(1,1,:))], ps_moving, ps_moving, st_moving);
74 % alignment box volumes
75 R_fixed_ab = imref3d([length(Vol_fixed_ab(:,1,1)), length(Vol_fixed_ab(1,:,1)), ...
76 length(Vol_fixed_ab(1,1,:))], ps_fixed, ps_fixed, st_fixed);
77 R_moving_ab = imref3d([length(Vol_moving_ab(:,1,1)), length(Vol_moving_ab(1,:,1)), ...
78 length(Vol_moving_ab(1,1,:))], ps_moving, ps_moving, st_moving);
79
80
81 %% 2. Rigid translational registration with Matlab toolkit:
82 % measure of similarity: multimodal Mutual Information
83 % (since both fixed and moving volumes differ in intensity)
84 [optimizer,metric]=imregconfig('multimodal');
85 optimizer.MaximumIterations = 300;
86 optimizer.InitialRadius = 0.004;
87 % registration on alignment box volumes!
88 t_matrix = imregtform(Vol_moving_ab,R_moving_ab,Vol_fixed_ab, R_fixed_ab, ...
89 'translation',optimizer,metric);
90
91
92 %% 3. Back-transformation to full 3D volume after registration
95
A Appendix
93 % full 3D volume transformation vectors in world coordinates
94 t_matrix.T(4,1) = trafo_fixed_ab(1) + t_matrix_ab.T(4,1) - trafo_moving_ab(1);
95 t_matrix.T(4,2) = trafo_fixed_ab(2) + t_matrix_ab.T(4,2) - trafo_moving_ab(2);
96 t_matrix.T(4,3) = trafo_fixed_ab(3) + t_matrix_ab.T(4,3) - trafo_moving_ab(3);
97
98
99 %% 4. Calculation of final registered isocenter-shift in linac coordinates:
100 % calculate center points of unregistered full 3D volume moving
101 centerXWorld_V_moving = mean(R_moving.XWorldLimits);
102 centerYWorld_V_moving = mean(R_moving.YWorldLimits);
103 centerZWorld_V_moving = mean(R_moving.ZWorldLimits);
104 % map center coordinates as coordinates after registration in coordinate
105 % system of fixed volume
106 [xWorld_V_moving,yWorld_V_moving,zWorld_V_moving] = ...
107 transformPointsForward(t_matrix,...
108 centerXWorld_V_moving,centerYWorld_V_moving,centerZWorld_V_moving);
109
110 % calculate final isocenter shift in LINAC world coordinate system
111 Linac_shift_RL_moving = xWorld_V_moving - ISO_fixed(1);
112 Linac_shift_AP_moving = (-1)*(yWorld_V_moving - ISO_fixed(2));
113 Linac_shift_CC_moving = (-1)*(zWorld_V_moving - ISO_fixed(3));
114
115
116 %% 5. Visualization of registered fixed (pCT) and moving (CBCT) volume
117
118 % determine full 3D registered moving volume
119 [Vol_reg,R_reg] = imwarp(Vol_moving,R_moving,t_matrix,...
120 'linear','OutputView',R_fixed);
121 % determine alignment box registered moving volume
122 [Vol_reg_ab,R_reg_ab] = imwarp(Vol_moving_ab,R_moving_ab,t_matrix_ab,...
123 'linear','OutputView',R_fixed_cb);
124
125 % choose significant slice to show or run a loop
126 i=50; j=18;
127
128 % convert from intrinsic to world coordinate system for full 3D volume
129 R_fixed_2d = imref2d([length(Vol_fixed(:,1,i)),...
130 length(Vol_fixed(1,:,i))],ps_fixed,ps_fixed);
131 R_moving_2d = imref2d([length(Vol_moving(:,1,i)),...
132 length(Vol_moving(1,:,i))],ps_moving,ps_moving);
133 R_reg_2d = imref2d([length(Vol_reg(:,1,i)),...
134 length(Vol_reg(1,:,i))], ps_fixed,ps_fixed);
135 % ... and alignment box
136 R_fixed_2d_ab = imref2d([length(Vol_fixed_ab(:,1,j)),...
137 length(Vol_fixed_ab(1,:,j))],ps_fixed,ps_fixed);
138 R_moving_2d_ab = imref2d([length(Vol_moving_ab(:,1,j)),...
139 length(Vol_moving_ab(1,:,j))],ps_moving,ps_moving);
140 R_reg_2d_ab = imref2d([length(Vol_reg_ab(:,1,j)),...
141 length(Vol_reg_ab(1,:,j))], ps_fixed,ps_fixed);
142
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143 % visualize "before" and "after" registration for full 3D volume
144 figure; imshowpair(Vol_moving(:,:,i),R_moving_2d,Vol_fixed(:,:,i),R_fixed_2d);
145 title('Unregistered axial slice, full 3D volume');
146 figure; imshowpair(Vol_reg(:,:,i),R_reg_2d,Vol_fixed(:,:,i),R_fixed_2d);
147 title('Registered axial slice, full 3D volume');
148 % ... and alignment box
149 figure; imshowpair(Vol_moving_ab(:,:,j),R_moving_2d_ab,...
150 Vol_fixed_ab(:,:,j),R_fixed_2d_ab);
151 title('Unregistered axial slice, alignment box');
152 figure; imshowpair(Vol_reg_ab(:,:,j),R_reg_2d_ab,...
153 Vol_fixed_ab(:,:,j),R_fixed_2d_ab);
154 title('Registered axial slice, alignment box');
155
156 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
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